POLYPEPTIDE, COMPOSITION, DETERGENT AND ANIMAL FEED COMPOSITION, ANIMAL FEED ADDITIVE, USE OF A POLY

专利摘要:
POLYPEPTIDE, COMPOSITION, DETERGENT AND ANIMAL FEED COMPOSITION, ANIMAL FEED ADDITIVE, USE OF A POLYPEEPTIDE, METHOD OF PRODUCTION OF A POLYPEEPTIDE, ISOLATED POLYNUCLEOTIDE, NUCLEIC ACID CONSTRUCT, AND VECTOR, EXPRESSION. The present invention relates to polypeptides having lysozyme and polynucleotide activity encoding the polypeptides. The present invention also relates to nucleic acid constructs, vectors, and host cells comprising polynucleotides as well as methods of producing and using polypeptides.
公开号:BR112014012160A2
申请号:R112014012160-5
申请日:2012-11-23
公开日:2020-06-23
发明作者:Matthew Schnorr Kirk；Kirk Matthew Schnorr
申请人:Novozymes A / S；
IPC主号:

专利说明:

[0001] [0001] This application contains a Sequence Listing in computer readable form, which is incorporated by reference.
[0002] [0002] The present invention relates to polypeptides having lysozyme activity, catalytic domains, and polynucleotides encoding polypeptides and catalytic domains. The present invention also relates to nucleic acid constructs, vectors, and host cells comprising polynucleotides as well as methods of producing and using polypeptides and catalytic domains. Description of the Related Art
[0003] [0003] Lysozyme is an O-glycosyl hydrolase produced as a defensive mechanism against bacteria by many organisms. The enzyme causes the hydrolysis of bacterial cell walls by cleaving the glycosidic bonds of the peptidoglycan; an important structural molecule in bacteria. After having their cell walls weakened by the action of lysozyme, the bacterial cells lys resulting from osmotic pressure.
[0004] [0004] Lysozyme occurs in many organisms such as viruses, plants, insects, birds, reptiles and mammals. In mammals, lysozyme was isolated from nasal secretions, saliva, tears, intestines, urine and milk. The enzyme cleaves the glycosidic bond between carbon number 1 of N-acetylmuramic acid and carbon number 4 of N-acetyl-D-glucosamine. In vivo,
[0005] [0005] There is growing interest in the potential of lysozyme enzymes as antimicrobial agents. For example, lysozyme activity has been shown against pathogens such as Streptococcus pneumoniae, Bacillus anthracis, Enterococcus faecium, Bacillus stearothermophilus, Clostridium botulinum, Clostridium butyricum, Clostridium perfringens, Clostridium sporogenes, Clostridium tildy and Clostridium tumeric, Clostridium tumeric and Clostridium tumeric.
[0006] [0006] Lysozyme was classified into five different families of glycoside hydrolases (GH) (CAZy, www.cazy.org): chicken egg white lysozyme (GH22), goose egg white lysozyme (GH23), lysozyme bacteriophage T4 (GH24), Sphingomonas flagellar protein (GH73) and Chalaropsis lysozymes (GH25). Lysozymes of the GH23 and GH24 families are mainly known to bacteriophages and have not been identified in fungi. It has been discovered that the GH25 lysozyme family is not structurally related to the other lysozyme family.
[0007] [0007] The use of lysozyme has been suggested in animal feed (see for example WO 00/21381 and WO 04/026334), in cheese production (see for example WO 05/080559), food preservation (Hughey and Johnson ( 1987) Appl Environ Microbiol 53: 2165), detergents (see for example US 5,041,236 and EP 0425016), in oral care (see for example US 4,355,022, WO 04/017988 and WO 08/124764), cosmetology and dermatology, contraception, urology , and gynecology (see for example WO 08/124764).
[0008] [0008] A GH25 lysozyme has been reported from Chalaropsis (Felsch JW, Ingagami T, and Hash JH. (1975), “The N, O-Diacetylmuramidase of Chalaropsis species; V The complete amino acid sequence, J. Biol. Chem. 250 (10): 3713-3720).
[0009] [0009] Chicken egg white lysozyme, which is the main commercially available product, does not cleave N, 6-O-
[00010] [00010] It has been observed that different lysozymes have different specificities in relation to different microorganisms. It is therefore desirable to have several lysozymes available in order to be able to select suitable enzymes for each particular application. New polypeptides having lysozyme activity are therefore desired. SUMMARY OF THE INVENTION
[00011] [00011] The present invention relates to isolated fungal polypeptides belonging to the GH23 or GH24 families and having lysozyme activity.
[00012] [00012] The present invention further relates to isolated polypeptides having lysozyme activity selected from the group consisting of: (a) a polypeptide having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the mature polypeptide of SEQ ID NO: 6; (b) a polypeptide having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96% at least 97%, at least 98%, at least 99% or 100% sequence identity with the mature polypeptide of SEQ ID NO: 2; (c) a polypeptide having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%,
[00013] [00013] The present invention also relates to isolated polynucleotides encoding the polypeptides of the present invention; nucleic acid constructs, recombinant expression vectors; recombinant host cells comprising polynucleotides; and methods of producing the polypeptides.
[00014] [00014] The present invention also relates to the polypeptides of the invention having antimicrobial activity and methods of using the polypeptides of the invention as inhibitors of biofilm formation, in detergent compositions, in animal feed and for the extraction of genomic DNA.
[00015] [00015] The present invention also relates to a polynucleotide encoding a signal peptide comprising or consisting of amino acids 1 to 19 of SEQ ID NO: 2, amino acids 1 to 20 of SEQ ID NO: 4 or amino acids 1 to 19 of SEQ ID NO: 6, which is operationally linked to a gene encoding a protein; nucleic acid constructs, expression vectors, and recombinant host cells comprising polynucleotides; and methods of producing a protein. Overview of String Listing
[00016] [00016] SEQ ID NO: 1 is the DNA sequence of the P8EH GH23 gene as isolated from Aspergillus aculeatus CBS 172.66.
[00017] [00017] SEQ ID NO: 2 is the amino acid sequence as deduced from SEQ ID NO: 1.
[00018] [00018] SEQ ID NO: 3 is the DNA sequence of the P242MS GH24 gene as an isolate from Acremonium alkalophilum CBS114.92.
[00019] [00019] SEQ ID NO: 4 is the amino acid sequence as deduced from SEQ ID NO: 3.
[00020] [00020] SEQ ID NO: 5 is the DNA sequence of the P244A7 GH24 gene as an isolate from Acremonium alkalophilum CBS114.92.
[00021] [00021] SEQ ID NO: 6 is the amino acid sequence as deduced from
[00022] [00022] SEQ ID NO: 7 is the DNA sequence of the P242M9 GH25 gene as an isolate of Acremonium alkalophilum CBS114.92.
[00023] [00023] SEQ ID NO: 8 is the amino acid sequence as deduced from SEQ ID NO: 7.
[00024] [00024] SEQ ID NO: 9 is the F-P8EH direct primer.
[00025] [00025] SEQ ID NO: 10 is the reverse primer R-P8EH.
[00026] [00026] SEQ ID NO: 11 is the F-P242MS direct primer.
[00027] [00027] SEQ ID NO: 12 is the reverse primer R-P242MS.
[00028] [00028] SEQ ID NO: 13 is the F-P244A7 forward primer.
[00029] [00029] SEQ ID NO: 14 is the reverse primer R-P244A7. Brief Description of the Figures
[00030] [00030] Figure 1 shows radial diffusion assays of Acremonium alcalophilum GH24 lysozyme (EXP03890, SEQ ID NO: 6), Acremonium alcalophilum GH25 lysozyme (EXP03864, SEQ ID NO: 8) and an Aspergillus GH25 reference lysozyme. fumigatus in S. carnosus and E.coli. DEFINITIONS
[00031] [00031] Lysozyme: The term "lysozyme" activity is defined here as an O-glycosyl hydrolase, which catalyzes the hydrolysis of the glycosidic bond between two or more carbohydrates, or between a carbohydrate and a non-carbohydrate fraction. Lysozymes cleave the glycosidic bond between certain residues in mucopolysaccharides and mucopeptides of bacterial cell walls, such as 1,4-beta bonds between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in a peptidoglycan and between N residues -acetyl-D-glucosamine in chitodextrins, resulting in bacteriolysis. Lysozyme belongs to the EC 3.2.1.17 enzyme class. For purposes of the present invention, lysozyme activity is determined according to the turbidity assay described in example 5. In one aspect, the polypeptides of the present invention are at least 20%, e.g., at least 40%, at least minus 50%,
[00032] [00032] Allelic variant: The term "allelic variant" means any one of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation occurs naturally through mutation, and can result in polymorphism within populations. Genetic mutations can be silent (no change in the encoded polypeptide) or can encode polypeptides having altered amino acid sequences. An allele variant of a polypeptide is a polypeptide encoded by an allele variant of a gene.
[00033] [00033] Antimicrobial activity: The term "antimicrobial activity" is defined here as an activity that kills or inhibits the growth of microorganisms, such as algae, archaea, bacteria, fungi and / or protozoa. The antimicrobial activity can for example be bactericidal meaning death of bacteria or bacteriostatic meaning prevention of bacterial growth. Antimicrobial activity may include catalysis of the hydrolysis of 1,4-beta bonds between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in a peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrins. Antimicrobial activity may also include binding of lysozyme to the surface of the microorganism and inhibiting its growth. The antimicrobial effect may also include the use of the lysozymes of the present invention for activation of bacterial autolysins, as an immunostimulator, by inhibiting or reducing bacterial toxins and by an opsonin effect. For purposes of the present invention, antimicrobial activity is determined according to the radial diffusion assay described in example 4.
[00034] [00034] Altered / modified property: The term "altered / modified property" is defined here as a characteristic associated with a
[00035] [00035] Thermostability: The term "thermostability" refers to the activity of lysozyme after an incubation period at elevated temperature in relation to the parent or an identified reference sequence, either in a buffer or under conditions such as those that exist during storage / product transportation or conditions similar to those that exist during industrial use of the variant. A variant may or may not exhibit an altered thermal activity profile in relation to the parent. In one aspect, the thermostability of the variant having lysozyme activity is at least 1.0 times, e.g., at least 1.1 times, at least 1.5 times, at least 1.8 times, at least 2 times at least 5 times, at least 10 times, at least 15 times, at least 20 times, or at least 25 times more thermostable than the parent or reference sequence at the selected temperature. Preferably, the activity is tested using the lysozyme turbidity activity assay described in the "Materials and Methods" section.
[00036] [00036] Temperature / temperature stability profile: The term "temperature / temperature stability profile" refers to the variant enzyme having a modified temperature profile compared to the parent or an identified reference sequence, where the profile of Temperature is determined as lysozyme activity as a function of temperature. The activity at each temperature is preferably indicated as a relative activity (in%) normalized to the value at the optimum temperature. The optimum temperature is that temperature within the tested temperatures (i.e. those with jumps of 5-10 ° C) where the activity is the highest.
[00037] [00037] pH stability: The term "pH stability" refers to the variant enzyme exhibiting structural stability in relation to the parent lysozyme or an identified reference sequence, after an incubation period at a pH that is outside the pH range where the enzyme is active (range of pH activities). Such a variant may or may not exhibit an altered pH activity profile in relation to the parent. For example, the variant may not be active at increased or decreased pH, but is able to maintain its three-dimensional structure and then regain activity as soon as it is returned to the pH activity range. Alternatively, the variant may have an improved ability to double in relation to the parent after incubation at increased or decreased pH.
[00038] [00038] In one aspect, the pH stability profile is changed such that a variant of lysozyme has improved stability at acidic pH. As used here, acidic pH means pH from 2 to 5.5, preferably from 2.5 to 5.25, more preferably from 3 to 5, even more preferably from 3.5 to 4. Preferably, the variant lysozyme maintains at least 40%, preferably at least 50%, 60%, 70% or 80%, more preferably at least 90%, even more preferably at least 95% residual activity after incubation at a given pH for 1 hour when compared to the variant that was maintained at pH 6.5 for the same time. Preferably, the residual activity of the variant lysozyme is at least 1.1 times, at least 1.3 times, at least 1.5 times, preferably at least 2 times, more preferably at least 5 times, most preferably at least 7 times , and even more preferably at least 10 times higher than the residual activity of the parent lysozyme or an identified reference sequence that was treated under the same conditions. Preferably, the activity is tested using the lysozyme turbidity activity assay described in the "Materials and Methods" section.
[00039] [00039] pH activity profile: The term "pH activity profile" is defined here as a variant lysozyme exhibiting a change in the pH-dependent activity profile when compared to the pH activity profile of the parent lysozyme or a sequence reference reference. The pH activity profile provides a measure of the enzyme's effectiveness in preventing microbial growth, eliminating microbial cells and / or catalyzing a hydrolysis reaction over a pH range under given conditions such as temperature and composition of the solvent. A lysozyme has a specific pH range in which the polypeptide is stable and retains its enzymatic activity, outside this range lysozyme becomes less active and potentially also less stable. Within the pH range, there is usually an optimal pH, where lysozyme shows the highest activity.
[00040] [00040] A variant of lysozyme with improved activity at alkaline pH (e.g., from pH 7.5 to 12, preferably from 8 to 11, more preferably from 8.5 to 10, even more preferably from 9 to 9, 5) will be able to function in more alkaline environments such as detergents.
[00041] [00041] A variant with improved activity at acidic pH (e.g., from pH 2 to 6.5, preferably from 2.5 to 6, more preferably from 3 to 5.5, even more preferably from 3.5 to 5) will be able to function under more acidic conditions, such as a preservative in certain foods or as a eubiotic molecule in diets.
[00042] [00042] In one aspect, the pH activity profile is changed such that a variant of lysozyme has improved activity at a more alkaline pH. Preferably, the activity of the lysozyme variant at a pH of at least 0.5 units higher, preferably at least 1.0 units higher, more preferably at least 1.5 units higher, even more preferably at least 2.0 units highest is at least 1.1 times, preferably at least 1.5 times, more preferably
[00043] [00043] In another aspect, the pH activity profile is changed such that a variant of lysozyme has improved activity at a more acidic pH. Preferably, the activity of the lysozyme variant at a pH of at least 0.5 units lower, preferably at least 1.0 units lower, more preferably at least 1.5 units lower, even more preferably at least 2.0 units lowest is at least 1.1 times, preferably at least 1.5 times, more preferably at least 2 times, even more preferably at least 5 times and most preferably at least 10 times higher than that of the parent enzyme or one identified reference string. Preferably, the lysozyme variant at the same time maintains at least 40%, preferably at least 50%, 60%, 70% or 80%, or 90%, more preferably at least 95%, even more preferably at least 100% of activity that the parent lysozyme or an identified reference sequence exhibits at its optimum pH. Preferably, the activity is tested using the lysozyme turbidity activity assay described in the "Materials and Methods" section.
[00044] [00044] Glycation Susceptibility: Non-enzymatic glycation is a spontaneous post-translational process where reducing sugars bind
[00045] [00045] Improved properties can also include thermal properties, such as pellet stability, steam stability, wider temperature activity profile. Additional improved properties may include sensitivity to protease, and / or glycosylation pattern. The improvements are preferably evaluated in relation to the desired application conditions.
[00046] [00046] Catalytic domain: The term "catalytic domain" means the region of an enzyme containing the catalytic machinery of the enzyme.
[00047] [00047] cDNA: The term "cDNA" means a DNA molecule that can be prepared by reverse transcription of a mature, processed mRNA molecule, obtained from a eukaryotic or prokaryotic cell. The cDNA has no intron sequences that can be present in the corresponding genomic DNA. The initial, primary RNA transcript is a precursor to mRNA that is processed through a series of steps, including processing, before appearing as processed mature mRNA,
[00048] [00048] Coding sequence: The term "coding sequence" means a polynucleotide, which directly specifies the amino acid sequence of a polypeptide. The boundaries of the coding sequence are generally determined by an open reading frame, which begins with a start codon such as ATG, GTG, or TTG and ends with a termination codon such as TAA, TAG, or TGA. The coding sequence can be genomic DNA, cDNA, synthetic DNA, or a combination thereof.
[00049] [00049] Control sequences: The term "control sequences" means nucleic acid sequences necessary for expression of a polynucleotide encoding a mature polypeptide of the present invention.
[00050] [00050] Expression: The term "expression" includes any step involved in the production of a polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
[00051] [00051] Expression vector: The term "expression vector" means a linear or circular DNA molecule that comprises a polynucleotide encoding a polypeptide and is operationally linked to control sequences that provide its expression.
[00052] [00052] Fragment: The term "fragment" means a polypeptide or catalytic domain having one or more (e.g., several) amino acids missing from the amino and / or carboxyl terminus of its mature polypeptide or domain; where the fragment has lysozyme activity. In one aspect, a fragment contains at least 198 amino acid residues (eg, amino acids 59 to 256 of SEQ ID NO: 2), or at least 230 amino acid residues (eg, amino acids 32 to 261 of SEQ ID NO: 2). In another aspect, a fragment contains at least 159 amino acid residues (e.g., amino acids 25 to 183 of SEQ ID NO: 4). In an additional aspect, a fragment contains at least 150 amino acid residues (eg, amino acids 24 to 173 of SEQ ID
[00053] [00053] Host cell: The term "host cell" means any cell type that is susceptible to transformation, transfection, transduction, or the like with a nucleic acid construct or expression vector comprising a polynucleotide of the present invention. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.
[00054] [00054] Isolated: The term "isolated" means a substance in a form or environment that does not occur in nature. Non-limiting examples of isolated substances include (1) any substance that does not occur naturally, (2) any substance including, but not limited to, any enzyme, variant, nucleic acid, protein, peptide or cofactor, which is at least partially removed of one or more or all naturally occurring constituents to which it is associated in nature; (3) any substance modified by man in relation to that substance found in nature; or (4) any substance modified by increasing the amount of the substance in relation to other components with which it is naturally associated (eg, multiple copies of a gene encoding the substance; use of a stronger promoter than the naturally associated promoter to the gene encoding the substance). An isolated substance may be present in a fermentation broth sample.
[00055] [00055] Mature polypeptide: The term "mature polypeptide" means a polypeptide in its final form after translation and any post-translational modifications, such as N-terminal processing, C-terminal truncation, glycosylation, phosphorylation, etc. In one aspect, the mature polypeptide is amino acids 20 to 264 of SEQ ID NO: 2, amino acids 21 to 186 of SEQ ID NO: 4 or amino acids 20 to 176 of SEQ ID NO: 6 based on the SignalP program (Nielsen et al., 1997, Protein
[00056] [00056] Mature polypeptide coding sequence: The term "mature polypeptide coding sequence" means a polynucleotide that encodes a mature polypeptide having lysozyme activity. In one aspect, the coding sequence for the mature polypeptide is the joined sequence of nucleotides 58 to 571 and nucleotides 639 to 859 of SEQ ID NO: 1, the joined sequence of nucleotides 61 to 267 and nucleotides 335 to 625 of SEQ ID NO: 1 : 3 or the joined sequence of nucleotides 58 to 133, nucleotides 215 to 345 and nucleotides 516 to 779 of SEQ ID NO: 5 based on the SignalP program (Nielsen et al., 1997, supra) which predicts that nucleotides 1 at 57 of SEQ ID NO: 1, nucleotides 1 to 60 of SEQ ID NO: 3 and nucleotides 1 to 57 of SEQ ID NO: 5 encode signal peptides.
[00057] [00057] Nucleic acid construct: The term "nucleic acid construct" means a nucleic acid molecule, single or double stranded, which is isolated from a naturally occurring gene or is modified to contain nucleic acid segments in a that otherwise would not exist in nature or that it is synthetic, that comprises one or more control sequences.
[00058] [00058] Operationally linked: The term "operationally linked" means a configuration in which a control sequence is placed in an appropriate position in relation to the coding sequence of a polynucleotide such that the control sequence directs the expression of the coding sequence.
[00059] [00059] Sequence identity: The relationship between two sequences of
[00060] [00060] For purposes of the present invention, the sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the program Needle of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277), preferably version 5.0.0 or higher. The parameters used are an open range penalty of 10, a range extension penalty of 0.5, and the replacement matrix EBLOSUM62 (EMBOSS version of BLOSUM62). The Needle result marked "longest identity" (obtained using the -nobrief option) is used as the percentage identity and is calculated as follows: (Identical Residues x 100) / (Alignment Length - Total Number of Intervals in Alignment)
[00061] [00061] For purposes of the present invention, the sequence identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, supra), preferably version 5.0.0 or higher. The parameters used are an open range penalty of 10, a range extension penalty of 0.5, and the substitution matrix EDNAFULL (EMBOSS version of NCBI NUC4.4). The Needle result marked "longest identity" (obtained using the -nobrief option) is used as the percentage identity and is calculated as follows: (Identical deoxyribonucleotides x 100) / (Alignment Length - Total Number of Alignment Intervals) .
[00062] [00062] Conditions of strictness: The different conditions of
[00063] [00063] The term “very low stringency conditions” means, for probes with at least 100 nucleotides in length, pre-hybridization and hybridization at 42ºC in 5X SSPE, 0.3% SDS, 200 micrograms / mL of sperm DNA of sheared and denatured salmon, and 25% formamide, following standard Southern transfer procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2X SSC, 0.2% SDS at 45 ° C.
[00064] [00064] The term “low stringency conditions” means, for probes with at least 100 nucleotides in length, pre-hybridization and hybridization at 42ºC in 5X SSPE, 0.3% SDS, 200 micrograms / mL of sperm DNA sheared and denatured salmon, and 25% formamide, following standard Southern transfer procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2X SSC, 0.2% SDS at 50 ° C.
[00065] [00065] The term “medium stringency conditions” means, for probes with at least 100 nucleotides in length, pre-hybridization and hybridization at 42ºC in 5X SSPE, 0.3% SDS, 200 micrograms / mL of sperm DNA sheared and denatured salmon, and 35% formamide, following standard Southern transfer procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2X SSC, 0.2% SDS at 55 ° C.
[00066] [00066] The term “medium-high stringency conditions” means, for probes with at least 100 nucleotides in length, prehybridization and hybridization at 42ºC in 5X SSPE, 0.3% SDS, 200 micrograms / mL of DNA of sheared and denatured salmon sperm and 35% formamide, following standard Southern transfer procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2X SSC, 0.2% SDS at 60 ° C.
[00067] [00067] The term “high stringency conditions” means, for probes with at least 100 nucleotides in length, pre-hybridization and hybridization at 42ºC in 5X SSPE, 0.3% SDS, 200 micrograms / mL of sperm DNA sheared and denatured salmon, and 50% formamide, following standard Southern transfer procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2X SSC, 0.2% SDS at 65 ° C.
[00068] [00068] The term “very high stringency conditions” means, for probes with at least 100 nucleotides in length, pre-hybridization and hybridization at 42ºC in 5X SSPE, 0.3% SDS, 200 micrograms / mL of sperm DNA of sheared and denatured salmon, and 50% formamide, following standard Southern transfer procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15 minutes using 2X SSC, 0.2% SDS at 70 ° C.
[00069] [00069] Subsequence: The term "subsequence" means a polynucleotide having one or more (e.g., several) nucleotides missing from the 5 'and / or 3' end of a sequence encoding the mature polypeptide; wherein the subsequence encodes a fragment having lysozyme activity. In one aspect, a subsequence contains at least 594 nucleotides (eg, the joined sequence of nucleotides 175 to 571 and nucleotides 639 to 835 of SEQ ID NO: 1), or at least 690 nucleotides (eg, the joined sequence of nucleotides 94 to 571 and nucleotides 639 to 850 of SEQ ID NO: 1). In another aspect, a subsequence contains at least 477 nucleotides (e.g., the joined sequence of nucleotides 73 to 267 and nucleotides 335 to 616 of SEQ ID NO: 3). In a further aspect, a subsequence contains at least 450 nucleotides (e.g., the joined sequence of nucleotides 70 to 133, nucleotides 215 to 345 and nucleotides 516 to 770 of SEQ ID NO: 5).
[00070] [00070] Substantially pure polynucleotide: The term
[00071] [00071] Substantially pure polypeptide: The term "substantially pure polypeptide" means a preparation that contains a maximum of 10%, a maximum of 8%, a maximum of 6%, a maximum of 5%, a maximum of 4%, a maximum of 3%, in maximum 2%, maximum 1%, and maximum 0.5% by weight of another polypeptide with which it is natively or recombinantly associated. Preferably, the polypeptide is at least 92% pure, e.g., at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, at least 99.5% pure, and 100% pure by weight of the total polypeptide material present in the preparation. The polypeptides of the present invention are preferably in a substantially pure form. This can be achieved, for example, by preparing the polypeptide by well-known recombinant methods or by classical purification methods.
[00072] [00072] Variant: The term "variant" means a polypeptide having lysozyme activity comprising a change, ie, a substitution, insertion, and / or deletion, of one or more (several) amino acid residues in one or more (e.g. several) positions. A substitution means replacing the amino acid by occupying a position with a different amino acid; a deletion means removal of the amino acid by occupying a position; and an insertion means adding 1, 2, or 3 amino acids adjacent to and immediately after the amino acid occupying the position. A variant according to the invention can comprise from 1 to 5; from 1 to 10; from 1 to 15; from 1 to 20; from 1 to 52; ie 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 , 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 , 50, 51 or 52 amendments.
[00073] [00073] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 80% mature polypeptide of SEQ ID NO: 2 which has lysozyme activity.
[00074] [00074] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 85% mature polypeptide of SEQ ID NO: 2 which has lysozyme activity.
[00075] [00075] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 2 of at least 90% which has lysozyme activity.
[00076] [00076] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 91% mature polypeptide of SEQ ID NO: 2 which has activity
[00077] [00077] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 92% mature polypeptide of SEQ ID NO: 2 which has lysozyme activity.
[00078] [00078] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 93% mature polypeptide of SEQ ID NO: 2 which has lysozyme activity.
[00079] [00079] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 2 of at least 94% which has lysozyme activity.
[00080] [00080] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 95% mature polypeptide of SEQ ID NO: 2 which has lysozyme activity.
[00081] [00081] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 96% mature polypeptide of SEQ ID NO: 2 which has lysozyme activity.
[00082] [00082] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 97% mature polypeptide of SEQ ID NO: 2 which has lysozyme activity.
[00083] [00083] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 98% mature polypeptide of SEQ ID NO: 2 which has lysozyme activity.
[00084] [00084] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 99% mature polypeptide of SEQ ID NO: 2 which has lysozyme activity.
[00085] [00085] In one aspect, polypeptides differ by no more than 52 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 , 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 , 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or 51, of the mature polypeptide of SEQ ID NO: 2.
[00086] [00086] A polypeptide of the present invention preferably comprises or consists of the amino acid sequence of SEQ ID NO: 2 or an allelic variant thereof; or it is a fragment of it having lysozyme activity. In another aspect, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 2. In another aspect, the polypeptide comprises or consists of amino acids 20 to 264 of SEQ ID NO: 2.
[00087] [00087] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 85% which has lysozyme activity.
[00088] [00088] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 90% which has lysozyme activity.
[00089] [00089] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 91% which has lysozyme activity.
[00090] [00090] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with the
[00091] [00091] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 93% that has lysozyme activity.
[00092] [00092] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 94% which has lysozyme activity.
[00093] [00093] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 95% which has lysozyme activity.
[00094] [00094] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 96% which has lysozyme activity.
[00095] [00095] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 97% mature polypeptide of SEQ ID NO: 4 which has lysozyme activity.
[00096] [00096] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 98% mature polypeptide of SEQ ID NO: 4 which has lysozyme activity.
[00097] [00097] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 99% mature polypeptide of SEQ ID NO: 4 which has activity
[00098] [00098] In one aspect, polypeptides differ by no more than 27 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 , 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26, of the mature polypeptide of SEQ ID NO:
[00099] [00099] A polypeptide of the present invention preferably comprises or consists of the amino acid sequence of SEQ ID NO: 4 or an allelic variant thereof; or it is a fragment of it having lysozyme activity. In another aspect, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 4. In another aspect, the polypeptide comprises or consists of amino acids 21 to 186 of SEQ ID NO: 4.
[000100] [000100] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 6 of at least 90% which has lysozyme activity.
[000101] [000101] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 6 of at least 91% which has lysozyme activity.
[000102] [000102] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 6 of at least 92% which has lysozyme activity.
[000103] [000103] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 6 of at least 93% which has lysozyme activity.
[000104] [000104] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with the
[000105] [000105] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 95% mature polypeptide of SEQ ID NO: 6 which has lysozyme activity.
[000106] [000106] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 6 of at least 96% which has lysozyme activity.
[000107] [000107] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity with at least 97% mature polypeptide of SEQ ID NO: 6 which has lysozyme activity.
[000108] [000108] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 6 of at least 98% which has lysozyme activity.
[000109] [000109] In one embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 6 of at least 99% which has lysozyme activity.
[000110] [000110] In one aspect, polypeptides differ by no more than 17 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 , 15 or 16, of the mature polypeptide of SEQ ID NO: 6.
[000111] [000111] A polypeptide of the present invention preferably comprises or consists of the amino acid sequence of SEQ ID NO: 6 or an allelic variant thereof; or it is a fragment of it having lysozyme activity. In another aspect, the polypeptide comprises or consists of the polypeptide
[000112] [000112] In another embodiment, the present invention relates to an isolated polypeptide having lysozyme activity encoded by a polynucleotide that hybridizes under medium stringency conditions, medium-high stringency conditions, high stringency conditions, or very stringent conditions high stringency with the mature polypeptide coding sequence of (i) SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5, (ii) your cDNA sequence, or (iii) the full length complement ( i) or (ii) (Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor, New York).
[000113] [000113] The polynucleotide of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 or a subsequence thereof, as well as the polypeptide of SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6 or a fragment thereof, can be used to design nucleic acid probes to identify and clone DNA encoding polypeptides having lysozyme activity from strains of different genera or species according to methods well known in the art. In particular, such probes can be used for hybridization with genomic DNA or cDNA of a cell of interest, following standard Southern transfer procedures, in order to identify and isolate the corresponding gene present there. Such probes can be considerably shorter than the entire sequence, but they must be at least 15, e.g., at least 25, at least 35, or at least 70 nucleotides in length. Preferably, the nucleic acid probe is at least 100 nucleotides in length, e.g., at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides, at least 600 nucleotides, at least 700 nucleotides, at least 800 nucleotides, or at least 900 nucleotides in length. DNA and RNA probes can be used. The probes are
[000114] [000114] A genomic DNA or cDNA library prepared from such other strains can be screened for DNA that hybridizes to the probes described above and encodes a polypeptide having lysozyme activity. Genomic or other DNA from such other strains can be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA can be transferred and immobilized on nitrocellulose or other suitable carrier material. In order to identify a clone or DNA that hybridizes to SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 or a subsequent one, the carrier material is used in a Southern blot.
[000115] [000115] For purposes of the present invention, hybridization indicates that polynucleotides hybridize with a labeled nucleic acid probe corresponding to (i) SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5; (ii) the coding sequence for the mature polypeptide of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5; (iii) your cDNA sequence; (iv) its full length complement; or (v) a subsequent one; under medium to very high stringency conditions. Molecules with which the nucleic acid probe hybridizes under these conditions can be detected using, for example, X-ray film or any other means of detection known in the art.
[000116] [000116] In one aspect, the nucleic acid probe is nucleotides 58 to 571 or nucleotides 639 to 859 of SEQ ID NO: 1, nucleotides 61 to 267 or nucleotides 335 to 625 of SEQ ID NO: 3, or nucleotides 58 to 133, nucleotides 215 to 345 or nucleotides 516 to 779 of SEQ ID NO:
[000117] [000117] In another embodiment, the present invention relates to an isolated polypeptide having lysozyme activity encoded by a polynucleotide having a sequence identity with the coding sequence of the mature polypeptide of SEQ ID NO: 1 or its cDNA sequence at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97% , at least 98%, at least 99%, or 100%.
[000118] [000118] In another embodiment, the present invention relates to an isolated polypeptide having lysozyme activity encoded by a polynucleotide having a sequence identity with the coding sequence of the mature polypeptide of SEQ ID NO: 3 or its CDNA sequence at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% , at least 99%, or 100%.
[000119] [000119] In another embodiment, the present invention relates to an isolated polypeptide having lysozyme activity encoded by a polynucleotide having a sequence identity with the coding sequence of the mature polypeptide of SEQ ID NO: 5 or its cDNA sequence at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% , or 100%.
[000120] [000120] In another embodiment, the present invention relates to variants of the mature polypeptide of SEQ ID NO: 2 comprising a substitution, deletion, and / or insertion at one or more (e.g., several) positions. In one embodiment, the number of substitutions, deletions
[000121] [000121] In a further embodiment, the present invention relates to variants of the mature polypeptide of SEQ ID NO: 4 comprising a substitution, deletion, and / or insertion at one or more (e.g., several) positions. In one embodiment, the number of amino acid substitutions, deletions and / or insertions introduced into the mature polypeptide of SEQ ID NO: 4 is no more than 27, eg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26.
[000122] [000122] In a further embodiment, the present invention relates to variants of the mature polypeptide of SEQ ID NO: 6 comprising a substitution, deletion, and / or insertion in one or more (e.g., several) positions. In one embodiment, the number of amino acid substitutions, deletions and / or insertions introduced into the mature polypeptide of SEQ ID NO: 6 is no more than 17, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16.
[000123] [000123] Amino acid changes may be of a minimal nature, that is, conservative amino acid substitutions or insertions that do not significantly affect protein folding and / or activity; small deletions, typically 1-30 amino acids; small extensions of the amino or carboxyl terminal, such as an amino-terminal methionine residue; a small binding peptide of up to 20-25 residues; or a small extension that facilitates purification by changing the total charge or other function, such as a polyhistidine tract, an antigenic epitope or a binding domain.
[000124] [000124] Examples of conservative substitutions are within the groups of basic amino acids (arginine, lysine and histidine), acidic amino acids
[000125] [000125] Alternatively, the amino acid changes are of such a nature that the physicochemical properties of the polypeptides are altered. For example, changes in amino acids can improve the thermal stability of the polypeptide, change substrate specificity, change the optimal pH, and the like.
[000126] [000126] Essential amino acids in a polypeptide can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine scanning mutagenesis (Cunningham and Wells, 1989, Science 244: 1081-1085). In the latter technique, simple alanine mutations are introduced into all residues of the molecule, and the resulting mutant molecules are tested for lysozyme activity to identify amino acid residues that are critical to the molecule's activity. See also, Hilton et al., 1996, J. Biol. Chem. 271: 4699-4708. The active site of the enzyme or other biological interaction can also be determined by physical analysis of the structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction, or photo-affinity tagging, in conjunction with contact site amino acid mutation putative. See, for example, de Vos et al., 1992, Science 255: 306-312; Smith et al., 1992, J. Mol. Biol. 224: 899-904;
[000127] [000127] Single or multiple amino acid substitutions, deletions, and / or insertions can be made and tested using known methods of mutagenesis, recombination and / or shuffling, followed by a relevant screening procedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988, Science 241: 53-57; Bowie and Sauer, 1989, Proc. Natl. Acad. Sci. USA 86: 2152-2156; WO 95/17413; or WO 95/22625. Other methods that can be used include error-prone PCR, phage display (eg, Lowman et al., 1991, Biochemistry 30: 10832-1037; U.S. Patent No. 5,223,409; WO 92/06204), and mutagenesis targeted to the region (Derbyshire et al., 1986, Gene 46: 145; Ner et al., 1988, DNA 7: 127).
[000128] [000128] High-throughput mutagenesis / shuffling methods, automated screening methods to detect the activity of mutated, cloned polypeptides expressed by host cells can be combined (Ness et al., 1999, Nature Biotechnology 17: 893-896). Mutagenized DNA molecules encoding active polypeptides can be recovered from host cells and quickly sequenced using standard methods in the art. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide.
[000129] [000129] The polypeptide can be a hybrid polypeptide in which a region of one polypeptide is fused at the N-terminus or C-terminus of a region of another polypeptide.
[000130] [000130] The polypeptide can be a fusion polypeptide or cleavable fusion polypeptide to which another polypeptide is fused at the N or C terminal of the polypeptide of the present invention. a
[000131] [000131] A fusion polypeptide may further comprise a cleavage site between the two polypeptides. After secretion of the fusion protein, the site is cleaved, releasing the two polypeptides. Examples of cleavage sites include, but are not limited to, sites disclosed in Martin et al., 2003, J. Ind. Microbiol. Biotechnol. 3: 568-576; Svetina et al., 2000, J. Biotechnol. 76: 245-251; Rasmussen-Wilson et al., 1997, Appl. Environ. Microbiol. 63: 3488-3493; Ward et al., 1995, Biotechnology 13: 498-503; and Contreras et al., 1991, Biotechnology 9: 378-381; Eaton et al., 1986, Biochemistry 25: 505-512; Collins-Racie et al., 1995, Biotechnology 13: 982-987; Carter et al., 1989, Proteins: Structure, Function, and Genetics 6: 240-248; and Stevens, 2003, Drug Discovery World 4: 35-48.
[000132] [000132] Polypeptide Sources Having Lysozyme Activity
[000133] [000133] A polypeptide having lysozyme activity of the present invention can be obtained from microorganisms of any gender. For purposes of the present invention, the term "obtained from" as used here in connection with a given source must mean that the polypeptide encoded by a polynucleotide is produced by the source or by a strain into which the polynucleotide from the source has been inserted. In one aspect, the polypeptide obtained from a given source is secreted extracellularly.
[000134] [000134] The polypeptide can be a fungal polypeptide. Per
[000135] [000135] In another aspect, the polypeptide is a polypeptide from Acremonium cellulolyticus, Aspergillus aculeatus, Aspergillus awamori, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus nidulans, Aspergillusporspornillosporn, keratosisporn, kosher, merdarium, Chrysosporium pannicola, Chrysosporium queenslandicum, Chrysosporium tropicum, Chrysosporium zonatum, Fusarium bactridioides, Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negambi, Fusarium negundi, Fusarium negundi, Fusarium, Fusarium sarcochroum, Fusarium sporotrichioides, Fusarium sulphureum, Fusarium torulosum, Fusarium trichothecioides, Fusarium venenatum, Humicola grisea, Humicola insolens, Humicola lanuginosa, Irpex lacteus, Mucor miehei, Myceliophthora thermophila, Neurospora cruman niculosum, Penicillium purpurogenum, Phanerochaete chrysosporium, Thielavia achromatica, Thielavia albomyces, Thielavia albopilosa, Thielavia australeinsis, Thielavia fimeti, Thielavia microspora, Thielavia ovispora, Thielavia peruviana, Thielaviaosteria, Thielavia terris, Thielavia terri, Thielavia Trichoderma longibrachiatum, Trichoderma reesei, or Trichoderma viride.
[000136] [000136] In another aspect, the polypeptide is a polypeptide from Aspergillus aculeatus or Acremonium alcalophilum, e.g., a polypeptide obtained from Aspergillus aculeatus CBS 172.66 or Acremonium alcalophilum CBS 114.92.
[000137] [000137] It will be understood that for the species mentioned above the invention encompasses both perfect and imperfect states, and other taxonomic equivalents, eg, anamorphs, regardless of the species name for which they are known. Those skilled in the art will readily recognize the identity of the appropriate equivalents.
[000138] [000138] Strains of these species are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).
[000139] [000139] The polypeptide can be identified and obtained from other sources including microorganisms isolated from nature (eg, soil, compounds, water, etc.) or DNA samples obtained directly from natural materials (eg, soil, compounds, water, etc.) using the above mentioned probes. Techniques for isolating microorganisms and DNA directly from natural habitats are well known in the art. A polynucleotide encoding the polypeptide can then be obtained by similar screening from a genomic DNA library or cDNA from another microorganism or mixed DNA sample. Once a polynucleotide encoding a polypeptide with the probe (s) has been detected, the polynucleotide can be isolated or cloned using techniques that are known to those of ordinary skill in the art (see, e.g., Sambrook et al. , 1989, supra). Polynucleotides
[000140] [000140] The present invention also relates to isolated polynucleotides encoding a polypeptide of the present invention, as described herein.
[000141] [000141] The techniques used to isolate or clone a polynucleotide are known in the art and include isolation from genomic or
[000142] [000142] Modification of a polynucleotide encoded a polypeptide of the present invention may be necessary for synthesis of polypeptides substantially similar to the polypeptide. The term "substantially similar" to the polypeptide refers to forms of the polypeptide that do not occur naturally. These polypeptides may differ in some way manipulated from the polypeptide isolated from its native source, e.g., variants that differ in specific activity, thermostability, optimal pH, or the like. Variants can be constructed based on the polynucleotide shown as the coding sequence for the mature polypeptide of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5, or its cDNA sequences, e.g. subsequence, and / or by introducing nucleotide substitutions that do not result in a change in the amino acid sequence of the polypeptide, but that correspond to the use of codons from the intended host organism for the production of the enzyme, or by introducing nucleotide substitutions that may give give rise to a different amino acid sequence. For a general description of
[000143] [000143] The present invention also relates to nucleic acid constructs comprising a polynucleotide of the present invention operably linked to one or more control sequences that direct expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences.
[000144] [000144] A polynucleotide can be manipulated in a variety of ways to provide expression of the polypeptide. The manipulation of the polynucleotide before insertion into a vector may be desirable or necessary depending on the expression vector. Techniques for modifying polynucleotides using recombinant DNA methods are well known in the art.
[000145] [000145] The control sequence can be a promoter, a polynucleotide that is recognized by a host cell for expression of a polynucleotide encoding a polypeptide of the present invention. The promoter contains transcriptional control sequences that mediate polypeptide expression. The promoter can be any polynucleotide that shows transcriptional activity in the host cell including mutant, truncated, and hybrid promoters, and can be obtained from genes encoding extracellular or intracellular polypeptides homologous or heterologous to the host cell.
[000146] [000146] Examples of suitable promoters for targeting the transcription of the nucleic acid constructs of the present invention in a bacterial host cell are the promoters obtained from the alpha-amylase (amyQ) gene from Bacillus amyloliquefaciens, alpha-amylase (amyL) gene from Bacillus licheniformis, Bacillus licheniformis (penP) gene, Bacillus maltogenic amylase (amyM) gene
[000147] [000147] Examples of suitable promoters for targeting the transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are the promoters obtained from the Aspergillus nidulans acetamidase genes, neutral Aspergillus niger alpha-amylase, stable acid alpha-amylase Aspergillus niger, Aspergillus niger glucoamylase (glaA) or Aspergillus awamori, Aspergillus oryzae TAKA amylase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomeric oxide oxide oxide oxide oxide oxide (7) Fusarium venenatum (WO 00/56900), Fusarium venenatum Daria (WO 00/56900), Fusarium venenatum quinn (WO 00/56900), Rhizomucor miehei lipase, Rhizomucor miehei aspartic proteinase, Trichoderma reesei beta-glucosidase, celobiohidrolol I from Trichoderma reesei, cellobiohydrolase II from Trichoderma reesei, endoglucanase I from Trichoderma reesei, endoglucanase II from Trich oderma reesei, endoglucanase III of Trichoderma reesei, endoglucanase IV of Trichoderma reesei, endoglucanase V of Trichoderma reesei, xylanase I of Trichoderma reesei, xylanase II of Trichoderma reesei, beta-xylidasidase of Trichoderma reesei, as well as promoter o reotori as well
[000148] [000148] In a yeast host, useful promoters are obtained from Saccharomyces cerevisiae enolase (ENO-1) genes, Saccharomyces cerevisiae galactokinase (GAL1), alcohol dehydrogenase / glyceraldehyde-3-phosphate dehydrogenase (ADH1, ADH2 / GAP) Saccharomyces cerevisiae, triose phosphate isomerase (TPI) from Saccharomyces cerevisiae, metallothionein (CUP1) from Saccharomyces cerevisiae, and Saccharomyces cerevisiae 3-phosphoglycerate kinase. Other useful promoters for yeast host cells are described by Romanos et al., 1992, Yeast 8: 423-488.
[000149] [000149] The control sequence can also be a transcription terminator, which is recognized by a host cell to terminate transcription. The terminator is operably linked to the 3 'terminal of the polynucleotide encoding the polypeptide. Any terminator that is functional in the host cell can be used in the present invention.
[000150] [000150] Preferred terminators for bacterial host cells are obtained from Bacillus clausii alkaline phosphatase (aprH) genes, Bacillus licheniformis alpha-amylase (amyL), and Escherichia coli ribosomal RNA (rrnB).
[000151] [000151] Preferred terminators for filamentous fungal host cells are obtained from the genes of the anthranilate synthase of Aspergillus nidulans, glucoamylase of Aspergillus niger, alpha-glucosidase of Aspergillus niger, TAKA amylase of Aspergillus oryzae and protease of the tyrosine tyrosine fusarium.
[000152] [000152] Preferred terminators for yeast host cells are obtained from Saccharomyces cerevisiae enolase genes, Saccharomyces cerevisiae cytochrome C (CYC1), and Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are described by Romanos et al., 1992, supra.
[000153] [000153] The control sequence can also be an mRNA stabilizing region downstream of a promoter and upstream of the coding sequence of a gene that increases gene expression.
[000154] [000154] Examples of suitable mRNA stabilizing regions are obtained from a Bacillus thuringiensis cryIIIA gene (WO 94/25612) and from a Bacillus subtilis SP82 gene (Hue et al., 1995, Journal of Bacteriology 177: 3465-3471) .
[000155] [000155] The control sequence can also be a leader, an untranslated region of an mRNA that is important for translation by the host cell. The leader is operably linked to the 5 'end of the polynucleotide encoding the polypeptide. Any leader that is functional in the host cell can be used.
[000156] [000156] Preferred leaders for filamentous fungal host cells are obtained from the Aspergillus oryzae TAKA amylase genes and Aspergillus nidulans phosphate isomerase triose.
[000157] [000157] Leaders suitable for yeast host cells are obtained from Saccharomyces cerevisiae enolase (ENO-1) genes, Saccharomyces cerevisiae 3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha factor and alcohol dehydrogenase / glyceraldehyde-3-phosphate dehydrogenase 2 / GAP) of Saccharomyces cerevisiae.
[000158] [000158] The control sequence can also be a polyadenylation sequence, a sequence operably linked to the 3 'terminal of the polynucleotide and, when transcribed, is recognized by the host cell
[000159] [000159] Preferred polyadenylation sequences for filamentous fungal host cells are obtained from Aspergillus nidulans anthranylate synthase genes, Aspergillus niger glucoamylase, Aspergillus niger alpha-glucosidase TAKA amylase from Fuserillos oryzae protease and protease tyrosine protease and protease protease .
[000160] [000160] Polyadenylation sequences useful for yeast host cells are described by Guo and Sherman, 1995, Mol. Cellular Biol. 15: 5983-5990.
[000161] [000161] The control sequence can also be a coding region of the signal peptide that encodes a signal peptide attached to the N-terminus of a polypeptide and that directs the polypeptide into the cell's secretory pathway. The 5 'end of the polynucleotide coding sequence can inherently contain a naturally occurring signal peptide coding sequence in the translation reading frame to the segment of the coding sequence encoding the polypeptide. Alternatively, the 5 'end of the coding sequence may contain a signal peptide coding sequence that is foreign to the coding sequence. A foreign signal peptide coding sequence may be required where the coding sequence does not naturally contain a signal peptide coding sequence. Alternatively, a foreign signal peptide coding sequence can simply replace the natural signal peptide coding sequence in order to enhance secretion of the polypeptide. However, any signal peptide coding sequence that directs the expressed polypeptide to the secretory pathway of a host cell can be used.
[000162] [000162] Effective signal peptide coding sequences for bacterial host cells are the signal peptide coding sequences
[000163] [000163] Effective signal peptide coding sequences for filamentous fungal host cells are the signal peptide coding sequences obtained from the Aspergillus niger neutral amylase genes, Aspergillus niger glucoamylase, Aspergillus oryzae TAKA amylase, Humicola insolens cellulase, endemic insolens cellulose, Humicola insolens, Humicola lanuginosa lipase, and Rhizomucor miehei aspartic proteinase.
[000164] [000164] Signal peptides useful for yeast host cells are obtained from the Saccharomyces cerevisiae alpha factor and Saccharomyces cerevisiae invertase genes. Other useful signal peptide coding sequences are described by Romanos et al., 1992, supra.
[000165] [000165] The control sequence can also be a pro-peptide coding sequence that encodes a pro-peptide positioned at the N-terminus of a polypeptide. The resulting polypeptide is known as a pro-enzyme or pro-polypeptide (or a zymogen in some cases). A pro-polypeptide is generally inactive and can be converted to an active polypeptide by catalytic or autocatalytic cleavage of the pro-peptide from the pro-polypeptide. The coding sequence of the pro-peptide can be obtained from Bacillus subtilis alkaline protease (aprE) genes, Bacillus subtilis neutral protease (nprT), Myceliophthora thermophila laccase (WO 95/33836), Rhizomucor miehei aspartic proteinase, and factor alpha of Saccharomyces cerevisiae.
[000166] [000166] Where both signal peptide and pro-peptide sequences are present, the pro-peptide sequence is positioned close to the
[000167] [000167] It may also be desirable to add regulatory sequences that regulate the expression of the polypeptide in relation to the growth of the host cell. Examples of regulatory systems are those that cause gene expression to turn on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems include lac, tac and trp operator systems. In yeast, the ADH2 system or GAL1 system can be used. In filamentous fungi, the Aspergillus niger glucomylase promoter, the Aspergillus oryzae TAKA alpha-amylase promoter, and the Aspergillus oryzae glucoamylase promoter can be used. Other examples of regulatory sequences are those that allow amplification of the gene. In eukaryotic systems, these regulatory sequences include the dihydrofolate reductase gene that is amplified in the presence of methotrexate, and metallothionein genes that are amplified with heavy metals. In these cases, the polynucleotide encoding the polypeptide would be operably linked to the regulatory sequence. Expression Vectors
[000168] [000168] The present invention also relates to recombinant expression vectors comprising a polynucleotide of the present invention, a promoter, and transcriptional and translational termination signals. The various nucleotide and control sequences can be joined to produce a recombinant expression vector that can include one or more convenient restriction sites to allow insertion or replacement of the polynucleotide encoding the polypeptide at such sites. Alternatively, the polynucleotide can be expressed by inserting the polynucleotide or a nucleic acid construct comprising the polynucleotide into an appropriate vector for expression. When creating the
[000169] [000169] The recombinant expression vector can be any vector (eg, a plasmid or virus) that can be conveniently subjected to recombinant DNA procedures and can cause expression of the polynucleotide. The choice of the vector will typically depend on the vector's compatibility with the host cell into which the vector is to be introduced. The vector can be a closed linear or circular plasmid.
[000170] [000170] The vector can be an autonomously replicating vector, ie, a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, eg, a plasmid, an extrachromosomal element, a minichromosome, or a artificial chromosome. The vector can contain any means to ensure self-replication. Alternatively, the vector can be one that, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome (s) in which it has been integrated. In addition, a single vector or plasmid or two or more vectors or plasmids can be used that together contain the total DNA to be introduced into the host cell genome, or a transposon.
[000171] [000171] The vector preferably contains one or more selectable markers that allow easy selection of transformed, transfected, transduced, or similar cells. A selectable marker is a gene whose product provides biocidal or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.
[000172] [000172] Examples of selectable bacterial markers are dal genes from Bacillus licheniformis or Bacillus subtilis, or markers that confer resistance to antibiotics such as resistance to ampicillin, chloramphenicol, kanamycin, neomycin, spectinomycin, or tetracycline.
[000173] [000173] The vector preferably contains an element (s) that allows the integration of the vector in the genome of the host cell or autonomous replication of the vector in the cell independent of the genome.
[000174] [000174] For integration into the host cell genome, the vector can be based on the polynucleotide sequence encoding the polypeptide or any other element of the vector for integration into the genome by homologous or non-homologous recombination. Alternatively, the vector may contain additional polynucleotides to target integration by homologous recombination in the host cell genome at a precise location (s) on the chromosome (s). To increase the likelihood of integration at a precise location, the integration elements must contain a sufficient number of nucleic acids, such as 100 to 10,000 base pairs, 400 to 10,000 base pairs, and 800 to 10,000 base pairs, which have a high degree of sequence identity with the corresponding target sequence to enhance the likelihood of homologous recombination. The integration elements can be any sequence that is homologous with the target sequence in the host cell genome. In addition, the integrating elements can be non-coding or coding polynucleotides. On the other hand, the vector can be integrated into the host cell genome by recombination
[000175] [000175] For autonomous replication, the vector may additionally comprise an origin of replication allowing the vector to replicate autonomously in the host cell in question. The origin of replication can be any plasmid replicator mediating autonomous replication that works in a cell. The term "origin of replication" or "plasmid replicator" means a polynucleotide that allows a plasmid or vector to replicate in vivo.
[000176] [000176] Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177 and pACYC184 allowing replication in E. coli, and pUB110, pE194, pTA1060 and pAMß1 allowing replication in Bacillus.
[000177] [000177] Examples of origins of replication for use in a yeast host cell are 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6.
[000178] [000178] Examples of useful origins of replication in a filamentous fungal cell are AMA1 and ANS1 (Gems et al., 1991, Gene 98: 61-67; Cullen et al., 1987, Nucleic Acids Res. 15: 9163-9175; WO 00/24883). Isolation of the AMA1 gene and the construction of plasmids or vectors comprising the gene can be achieved according to the methods disclosed in WO 00/24883.
[000179] [000179] More than one copy of a polynucleotide of the present invention can be inserted into a host cell to increase production of a polypeptide. An increase in the number of copies of the polynucleotide can be obtained by integrating at least one additional copy of the sequence into the genome of the host cell or by including a selectable marker gene amplifiable with the polynucleotide where cells containing amplified copies of the selectable marker gene, and additional copies of the polynucleotide can be selected by culturing the
[000180] [000180] The procedures used to link the elements described above to construct the recombinant expression vectors of the present invention are well known to a person skilled in the art (see, e.g., Sambrook et al., 1989, supra). Peptide Sign
[000181] [000181] The present invention also relates to an isolated polynucleotide encoding a signal peptide comprising or consisting of amino acids 1 to 19 of SEQ ID NO: 2, amino acids 1 to 20 of SEQ ID NO: 4 or amino acids 1 to 19 of SEQ ID NO: 6. Polynucleotides may additionally comprise a gene encoding a protein, which is operably linked to the signal peptide. The protein is preferably foreign to the signal peptide. In one aspect, the polynucleotide encoding the signal peptide is nucleotides 1 to 57 of SEQ ID NO: 1, nucleotides 1 to 60 of SEQ ID NO: 3 or nucleotides 1 to 57 of SEQ ID NO: 5.
[000182] [000182] The present invention also relates to nucleic acid constructs, expression vectors and recombinant host cells comprising such polynucleotides.
[000183] [000183] The present invention also relates to methods of producing a protein, comprising (a) culturing a recombinant host cell comprising such a polynucleotide; and (b) protein recovery.
[000184] [000184] The protein can be native or heterologous to a host cell. The term "protein" is not intended here to refer to a specific length of the encoded product, and therefore includes peptides, oligopeptides, and polypeptides. The term "protein" also encompasses two or more polypeptides combined to form the encoded product. Proteins also include hybrid polypeptides and
[000185] [000185] Preferably, the protein is a hormone, enzyme, receptor or its portion, antibody or its portion, or reporter. For example, the protein can be a hydrolase, isomerase, ligase, lyase, oxidoreductase, or transferase, e.g., an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellobiohydrolase, cellulase, chitinase, cutinase, cyclodextrin, glycosyltransferase, glycosyltransferase, glycosyltransferase, glycyltransferase, glycosylase, glucanstransferase, glucosamine endoglucanase, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, ribase, proteolytic enzyme xylanase, or beta-xylosidase.
[000186] [000186] The gene can be obtained from any prokaryotic, eukaryotic, or other source. Host Cells
[000187] [000187] The present invention also relates to recombinant host cells, comprising a polynucleotide of the present invention operably linked to one or more control sequences that direct the production of a polypeptide of the present invention. A construct or vector comprising a polynucleotide is introduced into a host cell such that the construct or vector is maintained as a chromosomal integral or as a self-replicating extrachromosomal vector as described above. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will depend largely on the gene encoding the polypeptide and its source.
[000188] [000188] The host cell can be any cell useful in the recombinant production of a polypeptide of the present invention, e.g., a prokaryote or a eukaryote.
[000189] [000189] The prokaryotic host cell can be any Gram-positive or Gram-negative bacteria. Gram-positive bacteria include, but are not limited to, Bacillus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, Oceanobacillus, Staphylococcus, Streptococcus, and Streptomyces. Gram-negative bacteria include, but are not limited to, Campylobacter, E. coli, Flavobacterium, Fusobacterium, Helicobacter, Ilyobacter, Neisseria, Pseudomonas, Salmonella, and Ureaplasma.
[000190] [000190] The bacterial host cell can be any Bacillus cell, including, but not limited to, Bacillus alkalophilus cells, Bacillus amyloliquefaciens, Bacillus brevis, Bacillus circulans, Bacillus clausii, Bacillus coagulans, Bacillus firmus, Bacillus lautus, Bacillus lentus , Bacillus licheniformis, Bacillus megaterium, Bacillus pumilus, Bacillus stearothermophilus, Bacillus subtilis, and Bacillus thuringiensis.
[000191] [000191] The bacterial host cell can also be any Streptococcus cell, including, but not limited to, Streptococcus equisimilis cells, Streptococcus pyogenes, Streptococcus uberis, and Streptococcus equi subsp. Zooepidemicus.
[000192] [000192] The bacterial host cell can also be any Streptomyces cell including, but not limited to, Streptomyces achromogenes cells, Streptomyces avermitilis, Streptomyces coelicolor, Streptomyces griseus, and Streptomyces lividans.
[000193] [000193] The introduction of DNA into a Bacillus cell can be carried out by transformation with protoplasts (see, eg, Chang and Cohen, 1979, Mol. Gen. Genet. 168: 111-115), transformation with competent cells (see, eg, Young and Spizizen, 1961, J. Bacteriol. 81: 823-829, or Dubnau and Davidoff-Abelson, 1971, J. Mol. Biol. 56: 209-221), electroporation (see, e.g., Shigekawa and Dower, 1988, Biotechniques 6: 742-751), or conjugation (see, e.g., Koehler and Thorne, 1987, J. Bacteriol. 169: 5271-5278). The introduction of DNA into an E. coli cell can be
[000194] [000194] The host cell can also be a eukaryote, such as a mammalian, insect, plant, or fungal cell.
[000195] [000195] The host cell can be a fungal cell. “Fungi” as used here includes the phylum Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota as well as the Oomycota and all the mitosporic fungi (as defined by Hawksworth et al., Em, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK).
[000196] [000196] The fungal host cell can be a yeast cell. “Yeast” as used here includes ascosporogenic yeast (Endomycetales), basidiosporogenic yeast, and yeast belonging to the Fungi Imperfecti
[000197] [000197] The yeast host cell may be a Candida, Hansenula, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces, or Yarrowia cell, such as a Kluyveromyces lactis cell, Saccharomyces carlsbergensis, Saccharomyces cerevisiae, Saccharomyyces, Saccharomyyces , Saccharomyces norbensis, Saccharomyces oviformis, or Yarrowia lipolytica.
[000198] [000198] The fungal host cell can be a filamentous fungal cell. “Filamentous fungi” include all filamentous forms in the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). Filamentous fungi are generally characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by stretching hyphae and carbon catabolism is mandatory aerobic. In contrast, vegetative growth by yeasts such as Saccharomyces cerevisiae is by flowering a single-celled stalk and carbon catabolism can be fermentative.
[000199] [000199] The filamentous fungal host cell can be a cell of Acremonium, Aspergillus, Aureobasidium, Bjerkandera, Ceriporiopsis, Chrysosporium, Coprinus, Coriolus, Cryptococcus, Filibasidium, Fusarium, Humicola, Magnaporthe, Mucoris, Paprika, Mycelor, Pyro, , Phanerochaete, Phlebia, Piromyces, Pleurotus, Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trametes, or Trichoderma.
[000200] [000200] For example, the filamentous fungal host cell can be
[000201] [000201] Fungal cells can be transformed by a process involving formation of protoplasts, transformation of protoplasts, and regeneration of the cell wall in a manner known per se. Suitable procedures for transforming Aspergillus and Trichoderma host cells are described in EP 238023, Yelton et al., 1984, Proc. Natl. Acad. Sci. USA 81: 1470-1474, and Christensen et al., 1988, Bio / Technology 6: 1419-1422. Suitable methods for transforming Fusarium species are described by Malardier et al., 1989, Gene 78: 147-156, and WO 96/00787. Yeast can be transformed using the procedures described by
[000202] [000202] The present invention also relates to methods of producing a polypeptide of the present invention, comprising (a) culturing a cell, which in its wild type produces the polypeptide, under conditions conducive to the production of the polypeptide; and (b) recovering the polypeptide. In a preferred aspect, the cell is an Aspergillus or Acremonium cell. In a more preferred aspect, the cell is a cell of Aspergillus aculeatus or Acremonium alcalophilum. In a most preferred aspect, the cell is a cell of Aspergillus aculeatus CBS172.66 or Acremonium alcalophilum CBS114.92.
[000203] [000203] The present invention also relates to methods of producing a polypeptide of the present invention, comprising (a) culturing a recombinant host cell of the present invention under conditions conducive to the production of the polypeptide; and (b) recovering the polypeptide.
[000204] [000204] Host cells are cultured in a nutrient medium suitable for producing the polypeptide using methods known in the art. For example, the cell can be grown by shaking flask or small or large scale fermentation (including continuous, batch, batch fed, or solid fermentation) in laboratory or industrial fermenters carried out in a suitable medium and under conditions allowing that the polypeptide is expressed and / or isolated. Cultivation takes place in a suitable nutrient medium comprising sources of carbon and nitrogen and inorganic salts, using procedures known in the art. Suitable means are available from commercial suppliers or
[000205] [000205] The polypeptide can be detected using methods known in the art that are specific to the polypeptides, for example, the lysozyme stain assay as described below. These detection methods include, but are not limited to, the use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay can be used to determine the activity of the polypeptide.
[000206] [000206] The polypeptide can be recovered using methods known in the art. For example, the polypeptide can be recovered from the nutrient medium by conventional procedures including, but not limited to, collection, centrifugation, filtration, extraction, spray drying, evaporation, or precipitation.
[000207] [000207] The polypeptide can be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures ( eg preparative isoelectric focus), differential solubility (eg ammonium sulfate precipitation), SDS-PAGE, or extraction (see, eg, Protein Purification, Janson and Ryden, editors, VCH Publishers , New York, 1989) to obtain substantially pure polypeptides.
[000208] [000208] In an alternative aspect, the polypeptide is not recovered, but instead a host cell of the present invention expressing the polypeptide is used as a source of the polypeptide. Plants
[000209] [000209] The present invention also relates to isolated plants, e.g., a plant, part of a plant, or transgenic plant cell, comprising a polynucleotide of the present invention in order to express and produce a polypeptide or domain in recoverable amounts . The polypeptide or domain can be recovered from the plant or plant part. Alternatively, the plant or plant part containing the polypeptide or domain can be used as such to improve the quality of a food or feed, eg, to improve nutritional value, palatability, and rheological properties, or to destroy an antinutritive factor .
[000210] [000210] The transgenic plant can be dicotyledonous (a dicot) or monocotyledonous (a monocot). Examples of monocot plants are grasses, such as grasses from the grassland (poacea, Poa), forage grasses such as Festuca, Lolium, temperate grasses such as Agrostis, and cereals, eg, wheat, oats, rye, barley, rice , sorghum, and corn.
[000211] [000211] Examples of dicot plants are tobacco, vegetables such as lupines, potatoes, sugar beet, peas, beans and soybeans, and cruciferous plants (Brassicaceae family), such as cauliflower, rapeseed, and the related model organism near Arabidopsis thaliana.
[000212] [000212] Examples of plant parts are stem, callus, leaves, root, fruits, seeds, and tubers, as well as the individual tissues comprising these parts, e.g., epidermis, mesophile, parenchyma, vascular tissues, meristems. Specific compartments of plant cells, such as chloroplasts, apoplasts, mitochondria, vacuoles, peroxisomes and cytoplasm, are also considered a plant part. Furthermore, any plant cell, regardless of the origin of the tissue, is considered to be a plant part. Likewise, parts of plants such as specific tissues and cells isolated to facilitate the use of the invention are also considered parts of plants, e.g., embryos, endospheres, aleurone and seed sediments.
[000213] [000213] Also included within the scope of the present invention is the progeny of such plants, parts of plants, and plant cells.
[000214] [000214] The transgenic plant or plant cell expressing the polypeptide or domain can be constructed according to methods known in the art. In summary, the plant or plant cell is constructed by incorporating one or more expression constructs encoding the polypeptide or domain in the genome of the host plant or chloroplast genome and propagation of the resulting modified plant or plant cell into a plant or cell transgenic plant.
[000215] [000215] The expression construct is conveniently a nucleic acid construct that comprises a polynucleotide encoding a polypeptide or domain operably linked to appropriate regulatory sequences required for expression of the polynucleotide in the plant or plant part of choice. Furthermore, the expression construct may comprise a selectable marker useful for identifying plant cells in which the expression construct and DNA sequences necessary for introducing the construct into the plant in question have been integrated (the latter depending on the method of introducing DNA to be used).
[000216] [000216] The choice of regulatory sequences, such as promoter and terminator sequences and optionally signal or transit sequences, is determined, for example, based on when, where, and how it is desired that the polypeptide or domain is expressed. For example, the expression of the gene encoding a polypeptide or domain can be constitutive or inducible, or it can be specific in terms of development, step or tissue, and the gene product can be targeted to a specific tissue or plant part such as seeds or sheets. Regulatory sequences are, for example, described by Tague et al., 1988, Plant Physiology 86: 506.
[000217] [000217] For constitutive expression, the 35S-CaMV promoter, corn ubiquitin 1, or rice actin 1 can be used (Franck et al., 1980,
[000218] [000218] A promoter-enhancing element can also be used to achieve higher expression of a polypeptide or domain in the plant. For example, the promoter intensifier element can be a
[000219] [000219] The selectable marker gene and any other parts of the expression construct can be chosen from those available in the art.
[000220] [000220] The nucleic acid construct is incorporated into the plant genome according to conventional techniques known in the art, including Agrobacterium-mediated transformation, virus-mediated transformation, microinjection, particle bombardment, biological transformation, and electroporation (Gasser et al. , 1990, Science 244: 1293; Potrykus, 1990, Bio / Technology 8: 535; Shimamoto et al., 1989, Nature 338: 274).
[000221] [000221] Agrobacterium tumefaciens-mediated gene transfer is a method for generating transgenic dicots (for a review, see Hooykas and Schilperoort, 1992, Plant Mol. Biol. 19: 15-38) and for transforming monocots, although other methods processing plants can be used for these plants. One method for generating transgenic monocots is to bombard particles (microscopic particles of another or tungsten coated with DNA transforms) from embryonic calluses or developing embryos (Christou, 1992, Plant J. 2: 275-281; Shimamoto, 1994, Curr Opin Biotechnol 5: 158-162; Vasil et al., 1992, Bio / Technology 10: 667-674). An alternative method for transforming monocots is based on transformation with protoplasts as described by Omirulleh et al., 1993, Plant Mol. Biol. 21: 415-428. Additional methods of transformation include those described in U.S. Patent Nos. 6,395,966 and 7,151,204 (both of which are incorporated herein by reference in their entirety).
[000222] [000222] After transformation, the transformants having incorporated the expression construct are selected and regenerated in whole plants of
[000223] [000223] In addition to the direct transformation of a particular plant genotype with a construct of the present invention, transgenic plants can be made by crossing a plant having the construct with a second plant which lacks the construct. For example, a construct encoding a polypeptide or domain can be introduced into a particular plant variety by crossing, without the need to directly transform a plant of that given variety. Therefore, the present invention encompasses not only a plant directly regenerated from cells that have been transformed in accordance with the present invention, but also the progeny of such plants. As used herein, offspring can refer to the offspring of any generation of a parent plant prepared in accordance with the present invention. Such an offspring may include a DNA construct prepared in accordance with the present invention. Crossbreeding results in the introduction of a transgene into a plant strain by cross-pollinating a starting strain with a donor plant strain. Non-limiting examples of such steps are described in U.S. Patent No. 7,151,204.
[000224] [000224] Plants can be generated through a process of retroconversion. For example, plants include plants referred to as genotype, lineage, inbreeding plant, or retroconverted hybrid.
[000225] [000225] Genetic markers can be used to assist the entry of one or more transgenes of the invention from one genetic fund to another. Selection aided by markers offers advantages over conventional breeding in that it can be used to avoid
[000226] [000226] The present invention also relates to methods of producing a polypeptide or domain of the present invention comprising (a) cultivating a transgenic plant or cell comprising a polynucleotide encoding the polypeptide or domain under conditions conducive to the production of the polypeptide or domain; and (b) recovering the polypeptide or domain. Uses
[000227] [000227] Examples of preferred uses of lysozyme or its compositions of the present invention are given below. The dosage of lysozyme and other conditions under which lysozyme is used can be determined based on methods known in the art.
[000228] [000228] The polypeptides of the invention are typically useful in any locus subject to contamination by bacteria, fungi, yeast or algae. Typically, the loci are in aqueous systems such as cooling water systems, laundry water, oily systems such as cutting oils, lubricants, oil fields and the like, where it is desired to kill microorganisms or at least control their growth . However, the present invention can also be used in all applications for which known lysozyme compositions are useful, such as
[000229] [000229] A lysozyme, or a composition thereof, of the present invention can be used in various applications to degrade a material comprising a peptidoglycan or a chitodextrin by treating the material with lysozyme or its composition (see for example Proctor and Cunningham, (1988 ) Critical Reviews in Food Science and Nutrition 26: 359-395; Carini et al. (1985) Microbiol. Food. Nutr. 3: 299–320; Hughey and Johnson (1987) Appl. Environ. Microbiol. 53: 2165–2170 ; Cunningham et al. (1991) World's Poultry Science Journal 47: 141-163). Uses of Invention Lysozymes for Cleaning and / or Detergents
[000230] [000230] A lysozyme of the present invention is preferably incorporated into and / or used in conjunction with detergent compositions as described below. When washing repeatedly at temperatures below 60ºC, there is an increased risk of bad smell in the washing machine (laundry as well as dishes) and in textiles or items washed in the machine. It is likely that this bad smell is caused by microbial organisms such as bacteria, fungi, algae or other single-celled organisms growing in the washing machine.
[000231] [000231] Furthermore, the invention relates to a process for washing fabrics comprising treating fabrics with a washing solution containing a detergent composition and a lysozyme or a lysozyme composition of the invention. The washing treatment can for example be carried out in a machine washing process or in a manual washing process. The washing solution can for example be an aqueous washing solution containing the detergent composition and having a pH between 3 and 12.
[000232] [000232] The fabrics subject to the methods of the present invention can be conventional washable clothing, for example household clothing.
[000233] [000233] The present invention provides a method of reducing microbial contamination on a surface, such as a textile garment or hard surface such as metal, plastic or rubber parts in a washing machine or dishwasher, bathroom tiles, floors, table tops, drains, sinks and lavatory, by treating the microbially contaminated surface with a lysozyme or lysozyme composition of the present invention. It is also expected that such a treatment will reduce the bad smell on textiles and hard surfaces containing microbial contamination.
[000234] [000234] The reduction of microbial contamination can be assessed in several ways, for example by letting a panel assess whether the smell has been diminished, alternatively a sample can be taken from the surface and cultured to assess whether the microbial count has been reduced as a result of the treatment compared to a treatment without lysozyme. Uses of Lysozymes of the Invention in Animal Feed
[000235] [000235] A lysozyme of the invention can also be used in animal feed. In one embodiment, the present invention provides a method for preparing an animal feed composition comprising adding a lysozyme of the present invention to one or more animal feed ingredients.
[000236] [000236] A lysozyme of the present invention can for example be used to stabilize the healthy microflora of animals, in particular cattle such as, but not limited to, sheep, goats, cattle (including, but not limited to, beef cattle, cows, and young calves), deer, pigs or pigs (including, but not limited to, piglets, growing pigs, and sows), poultry (including, but not limited to, geese, turkeys, ducks and chickens such as chickens , chicks and laying hens); horses, moose and rabbits but also fish (including but not limited to salmon, tilapia, catfish and carp; and crustaceans (including but not limited to shrimp and prawns)). In a preferred embodiment, lysozyme replaces antibiotics in animal diets. In a further embodiment, a lysozyme of the present invention is used as a feed additive, where it can provide a positive effect on the microbial balance of the chicken's digestive tract and thereby improve the performance of the animal.
[000237] [000237] A lysozyme of the present invention can also be used in animal feed as feed-enhancing enzymes that improve feed digestibility to improve the effectiveness of its use according to WO 00/21381 and WO 04/026334.
[000238] [000238] In an additional embodiment, a lysozyme of the present invention can be used as a feed additive, where it can provide a positive effect on the animal's digestive tract and thereby improve the animal's performance according to weight gain, feed conversion ratio (FCR), or improved animal health such as reduced mortality rate. The FCR is calculated as the feed intake in g / animal in relation to the weight gain in g / animal. Uses of Invention Lysozymes as Antimicrobial Agents
[000239] [000239] A lysozyme of the present invention can be used as antimicrobial agents. One aspect of the present invention is a method for
[000240] [000240] To assess whether a lysozyme of the present invention is capable of acting as an antimicrobial agent, it can be tested in a turbidity assay. In this assay, it is tested whether lysozyme is capable of degrading microbial cells eg a dry substrate of Exiguobacterium undae cells (isolated from a stinking sock) or cells of Micrococcus luteus dissolved in buffer or detergent, and thereby reducing the optical density (OD) at eg 540 nm, when compared to a microbial suspension only treated with buffer. Uses of Invention Lysozymes for Disinfection or as a Disinfectant
[000241] [000241] A lysozyme of the present invention may be useful as a disinfectant or used for disinfection, eg for treating infections in the eye or mouth, or for cleaning and disinfecting contact lenses, and for preventing or removing biofilm on a surface according to US Patent No. 6,777,223.
[000242] [000242] A lysozyme of the present invention can also be used in oral care. For example, lysozyme can be used alone or in combination with other enzymes or even antimicrobial peptides in toothpaste or other oral care products. Polypeptides can be introduced into the oral cavity or applied to an article that is to be introduced into the oral cavity. See for example WO 08/124764.
[000243] [000243] In general, it is contemplated that the polypeptides of the present invention are useful for cleaning, disinfecting or inhibiting microbial growth on any surface. Examples of surfaces, which can be advantageously contacted with the polypeptides of the invention, are process equipment surfaces used in, for example, dairy, chemical or pharmaceutical processing plants, water sanitation systems, oil processing plants, factories pulp processing
[000244] [000244] The polypeptides of the invention can additionally be used for cleaning surfaces and kitchen utensils in food processing plants and in any area where food is prepared or served such as hospitals, nursing homes and restaurants. Uses of Invention Lysozymes in Food Applications
[000245] [000245] A lysozyme of the present invention can also be used to selectively inhibit the uncontrolled growth of Clostridium tyrobutyricum during the ripening of cheeses, in particular those made from pressed and cooked curds, eg Swiss cheese, Parmesan, Edam, Gouda, Cheddar, and many others.
[000246] [000246] A lysozyme of the present invention can also be used in winemaking, to control or inhibit microbial contamination. Uses of Invention Lysozymes as Treatments
[000247] [000247] A lysozyme of the present invention can also be used in the topical treatment of dystrophic and inflammatory lesions of the skin and soft tissues. See for example Palmieri and Boraldi (1977) Arch. Sci. Med. (Torino) 134: 481-
[000248] [000248] A lysozyme of the present invention can also be used in skin care. For example, the polypeptide is applied to the skin of a patient suffering from a skin infection, such as acne. Lysozyme can also be used in a wound treatment, which is applied to the injured skin, for example, to aid in healing the wound. See, for example, U.S. Application No. 20080254079.
[000249] [000249] A lysozyme of the present invention can also be used in lipstick, lip balm, lip gel, or lip gloss. Per
[000250] [000250] A lysozyme of the present invention can also be used in the treatment of bronchopulmonary diseases.
[000251] [000251] A lysozyme of the present invention can also be used as digestive enzymes or digestive aids. A lysozyme of the present invention can also be used to improve the use of dead / living bacteria as a food source, e.g., by controlling unwanted microbial contaminants.
[000252] [000252] A lysozyme of the present invention can also be used as a therapeutic in a human or other animal, e.g., to control or inhibit bacterial overgrowth in the intestines of a human suffering from a disease, e.g., pancreatic disease. or an immunocompromised patient.
[000253] [000253] Uses of Lysozymes of the Invention for Extraction of Bacterial Genomic DNA
[000254] [000254] A lysozyme of the present invention can also be used in the extraction of bacterial genomic DNA. In order to be able to sequence bacterial DNA, the bacterial cell wall needs to be broken down to isolate the DNA within it. The cell wall of especially Gram-positive bacteria can be difficult to break down.
[000255] [000255] The lysozyme of chicken egg white is the standard enzyme used for DNA isolation from Gram-positive bacteria and works by hydrolysis of the peptidoglycan chains present in the cell wall thereby assisting in the degradation of cell walls. However, some Gram-positive cell walls are not degraded by lysozymes from chicken egg white. For example, it is recommended that cells, eg Staphylococcus aureus, be lysed with lysostaffin as described by Pitcher and Saunders (1989), App. Environ. Microbiol. 56 (3): 782-787. However, these methods
[000256] [000256] A lysozyme of the present invention can also be used to control microbial growth in a fermentation process, such as in the manufacture of ethanol or other products from biomass. See, for example, WO 2007/109750. Accordingly, lysozyme can be used, eg, in a process for producing a fermentation product comprising (a) liquefaction and / or saccharification of a carbohydrate material and (b) fermentation using a fermenting organism, in which a lysozyme of the present invention is applied to the fermentation process before, during and / or after fermentation in sufficient concentrations to kill and / or inhibit the growth of bacterial cells.
[000257] [000257] A lysozyme of the present invention can also be used to control microbial growth in fish or shrimp ponds.
[000258] [000258] Other uses include preserving food, beverages, cosmetics such as lotions, creams, gels, ointments, soaps, shampoos, conditioners, antiperspirants, deodorants, enzyme formulations, or food ingredients. Compositions
[000259] [000259] Still in a further aspect, the present invention relates to compositions comprising a polypeptide of the present invention having antimicrobial and / or lysozyme activity.
[000260] [000260] The composition can comprise a polypeptide of the present invention as the main enzyme component, e.g., a monocomponent composition. Alternatively, the composition can comprise multiple enzymatic activities, such as an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase,
[000261] [000261] The compositions can be prepared according to methods known in the art and can be in the form of a liquid or dry composition. For example, the polypeptide composition can be in the form of a granulate or a microgranulate. The polypeptide to be included in the composition can be stabilized according to methods known in the art.
[000262] [000262] Examples of preferred uses of the polypeptide compositions of the invention are given below. The dosage of the polypeptide composition of the invention and other conditions under which the composition is used can be determined based on methods known in the art. Animal Feed Compositions
[000263] [000263] The present invention is also directed to methods for using the polypeptides of the present invention having lysozyme activity in animal feed, as well as to feed compositions and feed additives comprising the lysozymes of the invention.
[000264] [000264] The term animal includes all animals, including humans. Examples of animals are non-ruminants, and ruminants. Ruminant animals include, for example, animals such as sheep, goats, and cattle, e.g., beef cattle and cows. In a particular embodiment, the animal is a non-ruminant animal. Non-ruminant animals include monogastric animals, eg, pigs or pigs (including, but not limited to, piglets, growing pigs, and sows); poultry such as turkeys, geese, ducks and chickens (including but not limited to broilers, laying hens); horses (including but not limited to blood
[000265] [000265] The term feed or feed composition means any compound, preparation, mixture, or composition suitable for or intended for use by an animal. In use according to the invention, lysozyme can be fed to the animal before, after, or simultaneously with the diet. The latter is preferred. Such lysozyme compositions can obviously be mixed with other enzymes.
[000266] [000266] Lysozyme can be added to the feed in any form, be it a relatively pure lysozyme or in mixture with other components intended for addition to animal feed, ie in the form of animal reaction additives, such as so-called pre-mixtures for animal food. In a further aspect, the present invention relates to compositions for use in animal feed, such as animal feed, and animal feed additives, e.g. premixes.
[000267] [000267] Other than the lysozyme of the invention, the animal feed additives of the invention contain at least one fat-soluble vitamin, and / or at least one water-soluble vitamin, and / or at least one trace mineral, and / or at least least one macromineral.
[000268] [000268] Additional optional feed additive ingredients are coloring agents, eg carotenoids such as beta-carotene, astaxanthin, and lutein; stabilizers; growth-enhancing additives and flavoring / flavoring compounds, eg creosol, anethole, deca-, undeca- and / or dodeca-lactones, ionones, irona, gingerol, piperidine, propylidene phthalide, butylidene phthalide, capsaicin and / or tannin ; polyunsaturated fatty acids (PUFAs); reactive oxygen generating species; also, a support that can contain, for example, 40-50% by weight of wood fibers, 8-10% by weight of stearin, 4-5% by weight of curcuma powder, 4-
[000269] [000269] A feed or feed additive of the invention may also comprise at least one other enzyme selected from phytase (EC
[000270] [000270] Examples of polyunsaturated fatty acids are C18, C20 and C22 polyunsaturated fatty acids, such as arachidonic acid, docosohexaenoic acid, eicosapentaenoic acid and gamma-linoleic acid.
[000271] [000271] Examples of reactive oxygen-generating species are chemicals such as perborate, persulfate, or percarbonate; and enzymes such as an oxidase, an oxygenase or a synthase.
[000272] [000272] Usually, vitamins soluble in fat and water, as well as trace minerals, form part of a so-called premix intended for addition to the feed, while macrominerals are usually separately added to the feed. Any of these types of composition, when enriched with a protease of the invention, is an animal feed additive of the invention.
[000273] [000273] In a particular embodiment, the animal feed additive of the invention is intended to be included (or prescribed as having to be included) in animal diets or animal feed at levels of 0.1 ppm to 1000 ppm, preferably 0.5 ppm to 200 ppm and more preferably 1 ppm to 100 ppm. The above mentioned dosage levels can also be used for premixes.
[000274] [000274] The animal feed composition of the invention may contain at least
[000275] [000275] The animal feed composition of the invention may also contain animal protein, such as meat and bone meal, feather meal and / or fish meal, typically in an amount of 0-25%. The animal feed composition of the invention may also contain Distilled Soluble Dry Grains (DDGS), typically in amounts of 0-30%.
[000276] [000276] Still in particular embodiments, the animal feed composition of the invention contains 0-80% corn; and / or sorghum 0-80%; and / or 0-70% wheat; and / or Barley at 0-70%; and / or 0-30% oats; and / or 0-40% soy flour; and / or fish meal at 0-25%; and / or meat and bone meal at 0-25%; and / or 0-20% buttermilk.
[000277] [000277] Animal diets can, for example, be manufactured as pureed feed (not pelleted) or pelleted feed. Typically, ground foods are mixed and sufficient amounts of essential vitamins and minerals are added according to the specifications for the species in question. Enzymes can be added as solid or liquid enzyme formulations. For example, for pureed feed, a solid or liquid enzyme formulation can be added before or during the mixing step of the ingredients. For pelleted feed, the
[000278] [000278] The final enzyme concentration in the diet is within the range of 0.01-200 mg of enzyme protein per kg of diet, for example in the range of 0.5-25 mg of enzyme protein per kg of diet. Cleaning or Detergent Compositions
[000279] [000279] The lysozyme of the invention can be added to and thus become a component of a detergent composition, particularly in a liquid detergent having a pH of 7 or less.
[000280] [000280] The detergent composition of the invention can for example be formulated as a detergent composition for manual or machine washing, including an additive laundry composition suitable for pretreating stained fabrics and an added fabric softener composition. for rinsing, or be formulated as a detergent composition for use in general household hard surface cleaning operations, or be formulated for manual or machine dishwashing operations.
[000281] [000281] In a specific aspect, the invention provides a detergent additive comprising the lysozyme of the invention. The detergent additive as well as the detergent composition can comprise one or more other enzymes such as a protease, a lipase, a cutinase, an amylase, a carbohydrase, a cellulase, a pectinase, a mannase, an arabinase, a galactanase, a xylanase , an oxidase, e.g., a laccase, and / or a peroxidase.
[000282] [000282] In general, the properties of the chosen enzyme (s) should
[000283] [000283] In one embodiment, the invention is directed to cleaning or detergent compositions comprising an enzyme of the present invention in combination with one or more additional cleaning components. The choice of additional cleaning components is within the skill of the specialist and includes conventional ingredients, including the exemplary non-limiting components shown below.
[000284] [000284] The choice of components may include, for textile treatment, consideration of the type of textile to be cleaned, the type and / or degree of soiling, the temperature at which cleaning is to take place, and the formulation of the product detergent. Although the components mentioned below are categorized according to a particular function, this should not be interpreted as a limitation since the component may have one or more additional features that the expert will appreciate.
[000285] [000285] The cleaning or detergent composition may be suitable for washing textiles such as fabrics, cloths or sheets, or for cleaning hard surfaces such as floors, tables, or dishwashing.
[000286] [000286] The invention also relates to polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. Surfactants
[000287] [000287] The detergent composition can comprise one or more surfactants, which can be anionic and / or cationic and / or non-ionic and / or semipolar and / or zwitterionic, or a mixture thereof. In a particular embodiment, the detergent composition includes a mixture of one or more
[000288] [000288] When included therein, the detergent will usually contain from about 1% to about 40% by weight, such as from about 5% to about%, including from about 5% to about 15%, or from about 20% to about 25% of an anionic surfactant. Non-limiting examples of anionic surfactants include sulfates and sulfonates, in particular, linear alkylbenzenesulfonates (LAS), LAS isomers, branched alkylbenzenesulfonates (BABS), phenylalkanesulfonates, alpha-olefinosulfonates (AOS), olefin sulfonates, 2-alkane sulfonates, sulfonates , 3-diylbis (sulfates), hydroxyalkanesulfonates and disulfonates, alkyl sulfates (AS) such as sodium dodecyl sulfate (SDS), fatty alcohol sulfates (FAS), primary alcohol sulfates (PAS), alcohol ether sulfates (AES or AEOS or FES, also known as alcohol ethoxysulfates or fatty alcohol ether sulfates), secondary alkanesulfonates (SAS), paraffin sulfonates (PS), sulfonate esters, glycerol sulfonated fatty acid esters, alpha-sulfur fatty acid methyl esters (alpha-SFMe or SES) including methyl sulfonate ester (MES), alkyl- or alkenyl succinic acid, dodecenyl / tetradecenyl succinic acid (DTSA), amino acid fatty acid derivatives, di esters and monoesters of sulfo-succinic acid or soap, and their combinations.
[000289] [000289] When included therein, the detergent will usually contain from about 0% to about 10% by weight of a cationic surfactant. Non-limiting examples of cationic surfactants include alkyldimethylethanolamine
[000290] [000290] When included therein, the detergent will usually contain from about 0.2% to about 40% by weight of a nonionic surfactant, for example from about 0.5% to about 30%, in particular of about 1% to about 20%, about 3% to about 10%, such as about 3% to about 5%, or about 8% to about 12%. Non-limiting examples of non-ionic surfactants include alcohol ethoxylates (AE or AEO), alcohol propoxylates, propoxylated fatty alcohols (PFA), alkoxylated fatty acid alkyl esters, such as ethoxylated and / or propoxylated fatty acid alkyl esters, alkylphenol ethoxylates (APE), nonylphenol ethoxylates (NPE), alkyl polyglycosides (APG), alkoxylated amines, fatty acid monoethanolamides (FAM), fatty acid diethanolamides (FAIR), ethoxylated fatty acid monoethanolamides (EFAM), propoxylated fatty acid (PFAM), polyhydroxy alkyl fatty acid amides, or N-acyl and N-alkyl glucosamine derivatives (glucamides, GA, or fatty acid glucamide, FAGA), as well as products available under the trade names SPAN and TWEEN , and their combinations.
[000291] [000291] When included therein, the detergent will usually contain from about 0% to about 10% by weight of a semipolar surfactant. Non-limiting examples of semipolar surfactants include amine oxides (AO) such as alkyldimethylamine oxide, N- (coconut alkyl) -N, N-dimethylamine oxide and N- (tallow-alkyl) -N, N-bis amine oxide (2-hydroxyethyl), fatty acid alkanolamides and ethoxylated fatty acid alkanolamides, and their combinations.
[000292] [000292] When included therein, the detergent will usually contain from about 0% to about 10% by weight of a zwitterionic surfactant.
[000293] [000293] A hydrotope is a compound that solubilizes hydrophobic compounds in aqueous solutions (or conversely, polar substances in a non-polar environment). Typically, hydrotopes are hydrophilic and hydrophobic in character (so-called amphiphilic properties as known from surfactants); however, the molecular structure of hydrotopes does not generally favor spontaneous self-aggregation, see eg review by Hodgdon and Kaler (2007), Current Opinion in Colloid & Interface Science 12: 121-128. The hydrotopes do not exhibit a critical concentration above which self-aggregation occurs as found in surfactants and lipids forming micellar, lamellar and other well-known mesophases. Instead, many hydrotopes show a continuous-type aggregation process where the sizes of the aggregates grow as the concentration increases. However, many hydrotopes alter the phase, stability, and colloidal properties of systems containing polar and non-polar substances, including mixtures of water, oil, surfactants, and polymers. Hydrotopes are classically used in various industries ranging from pharmaceutical, personal care, food, to technical applications. The use of hydrotopes in detergent compositions allows for example formulations of more concentrated surfactants (as in the process of compacting liquid detergents by removing water) without inducing unwanted phenomena such as phase separation or high viscosity.
[000294] [000294] The detergent may contain 0-5% by weight, such as about 0.5 to about 5%, or about 3% to about 5% of a hydrope. Any hydrotope known in the art for use in detergents may be used. Non-limiting examples of hydrotopes include sodium benzenesulfonate, sodium p-toluenesulfonate (STS), sodium xylenesulfonates (SXS),
[000295] [000295] The detergent composition can contain about 0-65% by weight, such as about 5% to about 45% of a detergent adjuvant or adjuvant, or a mixture thereof. In a dishwashing detergent, the level of adjuvant is typically 40-65%, particularly 50-65%. The adjuvant and / or adjuvant can be particularly a chelating agent that forms water-soluble complexes with Ca and Mg. Any adjuvant and / or co-adjuvant known in the art for use in laundry detergents can be used. Non-limiting examples of adjuvants include zeolites, diphosphates (pyrophosphates), triphosphates such as sodium triphosphate (STP or STPP), carbonates such as sodium carbonate, soluble silicates such as sodium metasilicate, layered silicates (eg, SKS -6 from Hoechst), ethanolamines such as 2-aminoetan-1-ol (MEA), diethanolamine (DEA, also known as iminodiethanol), triethanolamine (TEA, also known as 2,2 ', 2 ”-nitrilotriethanol), and inulin carboxymethyl (CMI), and their combinations.
[000296] [000296] The detergent composition can also contain 0-20% by weight, such as about 5% to about 10% of a detergent adjuvant, or a mixture thereof. The detergent composition can include an adjuvant alone, or in combination with an adjuvant, for example a zeolite adjuvant. Non-limiting examples of adjuvants include polyacrylate homopolymers or their copolymers, such as poly (acrylic acid) (PAA) or copoly (acrylic acid / maleic acid) (PAA / PMA). Other non-limiting examples include citrate, chelators such as aminocarboxylates, aminopolicarboxylates and phosphonates, and alkyl- or
[000297] [000297] The detergent can contain 0-50% by weight, such as about 0.1% to about 25%, of a bleaching system. Any bleaching system known in the art for use in laundry detergents can be used. Suitable bleaching system components include bleaching catalysts,
[000298] [000298] The detergent may contain 0-10% by weight, such as 0.5-5%, 2-5%, 0.5-2% or 0.2-1% of a polymer. Any polymer known in the art for use in detergents may be used. The polymer can function as an adjuvant as mentioned above, or it can
[000299] [000299] The detergent compositions of the present invention can also include fabric coloring agents such as dyes or pigments, which when formulated in detergent compositions can be deposited on a fabric when said fabric is contacted with a washing liquor comprising said compositions detergents and thus changing the shade of said fabric through absorption / reflection of visible light. Fluorescent bleaching agents emit at least some visible light. In contrast, tissue coloring agents change the tone of a surface as they absorb at least a portion of the visible light spectrum. Suitable tissue coloring agents include
[000300] [000300] In one aspect, the present invention provides a detergent additive comprising a lysozyme of the present invention. The detergent additive as well as the detergent composition can comprise one or more [additional] enzymes such as a protease, lipase, cutinase, an amylase, carbohydrase, cellulase, pectinase, mannase, arabinase, galactanase, xylanase, oxidase, e.g. , a laccase, and / or peroxidase.
[000301] [000301] In general, the properties of the selected enzyme (s) must be compatible with the selected detergent (ie, optimal pH, compatibility with other enzymatic and non-enzymatic ingredients, etc.) and the (s) enzyme (s) must be present in effective amounts.
[000302] [000302] Cellulases: Suitable cellulases include those from
[000303] [000303] Especially suitable cellulases are alkaline or neutral cellulases having color care benefits. Examples of such cellulases are cellulases described in EP 0 495 257, EP 0 531 372, WO 96/11262, WO 96/29397, WO 98/08940. Other examples are variants of cellulases such as those described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471, WO 98/12307 and PCT / DK98 / 00299.
[000304] [000304] Commercially available cellulases include Celluzyme, and Carezyme (Novozymes A / S), Clazinase, and Puradax HA (Genencor International Inc.), and KAC-500 (B)  (Kao Corporation).
[000305] [000305] Proteases: Suitable proteases include those of animal, vegetable or microbial origin. Preferential origin is preferred. Chemically modified or protein manipulated mutants are included. The protease can be a serine protease or a metalloprotease, preferably an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from Bacillus, e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168 (described in WO 89/06279). Examples of trypsin-type proteases are trypsin (e.g., of porcine or bovine origin) and the Fusarium protease described in WO 89/06270 and WO 94/25583.
[000306] [000306] Examples of useful proteases are the variants described in WO 92/19729, WO 98/20115, WO 98/20116, and WO 98/34946, especially the variants with substitutions in one or more of the following positions: 27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 194, 206, 218, 222, 224, 235, and
[000307] [000307] Preferred commercially available protease enzymes include Alcalase, Savinase, Primase, Duralase, Esperase, and Kannase (Novozymes A / S), Maxatase, Maxacal, Maxapem, Properase, Purafect, Purafect OxP, FN2, and FN3 (Genencor International Inc.).
[000308] [000308] Lipases and Cutinases: Suitable lipases and cutinases include those of bacterial or fungal origin. Chemically modified or protein-manipulated mutant enzymes are included. Examples include Thermomyces lipase, eg from T. lanuginosus (previously named Humicola lanuginosa) as described in EP258068 and EP305216, Humicola cutinase, eg H. insolens (WO96 / 13580), lipase from Pseudomonas strains ( some of these now renamed Burkholderia), eg P. alcaligenes or P. pseudoalcaligenes (EP218272), P. cepacia (EP331376), P. sp. SD705 (WO95 / 06720 & WO96 / 27002), P. wisconsinensis (WO96 / 12012), GDSL-type lipases from Streptomyces (WO10 / 065455), Magnaporthe grisea cutinase (WO10 / 107560), Pseudomonas mendocina cutinase (US5,389,536 ), Thermobifida fusca lipase (WO11 / 084412), Geobacillus stearothermophilus lipase (WO11 / 084417), Bacillus subtilis lipase (WO11 / 084599), and Streptomyces griseus lipase (WO11 / 150157) and S. pristinaespiralis (WO12 / 137 ).
[000309] [000309] Other examples are variants of lipase such as those described in EP407225, WO92 / 05249, WO94 / 01541, WO94 / 25578, WO95 / 14783, WO95 / 30744, WO95 / 35381, WO95 / 22615, WO96 / 00292, WO97 / 04079, WO97 / 07202, WO00 / 34450, WO00 / 60063, WO01 / 92502, WO07 / 87508 and WO09 / 109500.
[000310] [000310] Preferred commercial lipase products include LipolaseTM, Lipex ™; LipolexTM and LipocleanTM (Novozymes A / S), Lumafast (originally from Genencor) and Lipomax (originally from Gist-Brocades).
[000311] [000311] Other examples are still lipases sometimes referred to as acyltransferases or perhydrolases, eg acyltransferases with homology with Candida antarctica lipase A (WO10 / 111143), Mycobacterium smegmatis acyltransferase (WO05 / 56782), perhidrolases of the family CE 7 (WO09 / 67279), and M. smegmatis perhydrolase variants, in particular the S54V variant used in the commercial product Gentle Power Bleach from Huntsman Textile Effects Pte Ltd (WO10 / 100028).
[000312] [000312] Amylases: Suitable amylases (α and / or β) include those of bacterial or fungal origin. Chemically modified or protein manipulated mutants are included. Amylases include, for example, α-amylases obtained from Bacillus, e.g., a special strain of Bacillus licheniformis, described in more detail in GB 1,296,839.
[000313] [000313] Examples of useful amylases are the variants described in WO 94/02597, WO 94/18314, WO 96/23873, and WO 97/43424, especially the variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 181, 188, 190, 197, 202, 208, 209, 243, 264, 304, 305, 391, 408 and 444.
[000314] [000314] Commercially available amylases are DuramylTM, TermamylTM, FungamylTM, Stainzyme TM, NatalaseTM and BANTM (Novozymes A / S), RapidaseTM and PurastarTM (from Genencor International Inc.).
[000315] [000315] Peroxidases / Oxidases: Suitable peroxidases / oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein manipulated mutants are included. Examples of useful peroxidases include Coprinus, e.g., C. cinereus peroxidases, and variants thereof such as those described in WO 93/24618, WO 95/10602 and WO 98/15257. Commercially available peroxidases include Guardzyme (Novozymes A / S).
[000316] [000316] The detergent enzyme (s) can be included in a detergent composition by adding separate additives containing one or more
[000317] [000317] Granules can be produced without dust formation, e.g., as disclosed in US 4,106,991 and 4,661,452 and can optionally be coated by methods known in the art. Examples of waxy coating materials are poly (ethylene oxide) products (polyethylene glycol, PEG) with average molar weights from 1000 to 20000; ethoxylated nonolfenols having 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluidized bed techniques are given in GB 1483591. Liquid enzyme preparations can, for example, be stabilized by the addition of a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Protected enzymes can be prepared according to the method disclosed in EP 238,216. Adjoining materials
[000318] [000318] Any detergent components known in the art for use in laundry detergents can be used. Other optional detergent components include anti-corrosion agents, anti-shrink agents, dirt repellent agents, anti-creaking agents, bactericides, binders, corrosion inhibitors, disintegrating / disintegrating agents, dyes, enzyme stabilizers (including boric acid, borates, CMC, and / or polyols such as propylene
[000319] [000319] Dispersants: The detergent compositions of the present invention can also contain dispersants. In particular, powder detergents can comprise dispersants. Suitable water-soluble organic materials include homo- or copolymeric acids or their salts, in which the polycarboxylic acid comprises at least two carboxyl radicals separated from each other by no more than two carbon atoms. Suitable dispersants are for example described in Powdered Detergents, Surfactant science series volume 71, Marcel Dekker, Inc.
[000320] [000320] Dye Transfer Inhibiting Agents: The detergent compositions of the present invention may also include one or more dye transfer inhibiting agents. Suitable dye transfer inhibiting agents include, but are not limited to, polyvinylpyrrolidone polymers, polyamine N-oxide polymers, N-vinylpyrrolidone and N-vinylimidazole copolymers, polyvinyloxazolidones and polyvinylimidazoles or mixtures thereof. When present in a subject composition, dye transfer inhibiting agents can be present at levels from about 0.0001% to about 10%, from about 0.01% to about 5% or even about 0.1% to about 3% by weight of the composition.
[000321] [000321] Fluorescent bleaching agent: Compositions
[000322] [000322] Dirt-release polymers: The detergent compositions of the present invention may also include one or more dirt-release polymers that assist in removing dirt from fabrics such as cotton and polyester-based fabrics, in particular in removing dirt hydrophobic polyester-based fabrics. The dirt-releasing polymers can for example be nonionic or anionic tereftalt-based polymers, polyvinyl caprolactam and related copolymers, vinyl graft copolymers, polyester polyamides, see for example Chapter 7 in Powdered Detergents, Surfactant science series, volume 71, Marcel Dekker, Inc. Another type of dirt releasing polymers are amphiphilic alkoxylated fat cleaning polymers comprising a core structure and a plurality of alkoxylate groups attached to that core structure. The core structure can comprise a polyalkylenimine structure or a polyalkanolamine structure as described in detail in WO 2009/087523 (incorporated herein by reference). In addition, random graft copolymers are suitable soil release polymers. Suitable graft copolymers are described in more detail in WO 2007/138054, WO 2006/108856 and WO 2006/113314 (incorporated herein by reference). Other dirt-releasing polymers are substituted polysaccharide structures, especially substituted cellulosic structures such as cellulosic derivatives such as those described in EP 1867808 or WO 2003/040279 (both are incorporated herein by reference). Suitable cellulosic polymers include cellulose, cellulose ethers, cellulose esters, cellulose amides and mixtures thereof. Suitable cellulosic polymers include anionically modified cellulose, non-anionically modified cellulose, cationically modified cellulose, zwitterionically modified cellulose, and mixtures thereof. Suitable cellulosic polymers include
[000323] [000323] Anti-reposition agents: The detergent compositions of the present invention may also include one or more anti-reposition agents such as carboxymethylcellulose (CMC), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), polyoxyethylene and / or polyethylene glycol (PEG), homopolymers acrylic acid, acrylic acid and maleic acid copolymers, and ethoxylated polyethyleneimines. The cellulose-based polymers described under dirt-releasing polymers can also function as anti-reposition agents.
[000324] [000324] Other suitable adjunct materials include, but are not limited to, anti-shrink agents, anti-aging agents, bactericides, binders, carriers, dyes, enzyme stabilizers, fabric softeners, fillers, foam regulators, hydrotropes, perfumes, pigments, suppressants of saponiferous solution, solvents, and structuring agents for liquid detergents and / or structure elasticizing agents. Biofilms
[000325] [000325] Microorganisms growing on biofilms are less susceptible to all types of antimicrobial agents than the same microorganisms when grown in conventional suspension cultures.
[000326] [000326] It is well known that starving bacteria can be much less susceptible to a variety of antimicrobial challenges. For example, a number of classic antibiotics such as penicillin perform poorly on slow or non-dividing bacteria. Because lysozyme attacks and destroys the peptidoglycan layer regardless of the growth state of the bacteria, it remains effective.
[000327] [000327] Biofilm control; exemplary dental water lines:
[000328] [000328] The constitution of biofilm within a dental waterline may contain biofilms consisting of Pseudomonas aeruginosa, Proteus mirabilis, Legionella sp. to name just a few. There is also the possibility of colonization of species generally found within the oral cavity as a result of the failure of anti-retraction valves within the system. The risk of cross-infection becomes even more of a potential risk of stroke when immunocompromised patients are involved and these days the numbers of patients within this category continue to grow steadily. There is a need for effective control of bacterial biofilm accumulation in dental waterlines. A review of biofilms can be found at: Watnick P and Kolter R (2000), “Biofilm, city of microbes”, J Bacteriol.; 182 (10): 2675-9.
[000329] [000329] A typical example of a commercial throat expectorant product is Lisopaine produced by: BOEHRINGER INGELHEIM
[000330] [000330] For local treatment of specific infections limited to the oral membranes of the oropharynx. Caution, if clinical indications of a general bacterial infection are evident, antibiotic therapy is advised. Toothpaste:
[000331] [000331] Lysozyme can be used alone or in combination with other enzymes or even antimicrobial peptides. Examples of other enzymes are glucose oxidase and lactoperoxidase.
[000332] [000332] A toothpaste composition including lysozyme is "Biotene" by Laclede, Inc., 2030 East University Drive, Rancho Domiguez, CA 90220, USA. Active Ingredients Contains: Lactoperoxidase (100 gm) Inactive Ingredients Glucose Oxidase, Lysozyme, Sodium Monofluorophosphate, Sorbitol, Glycerin, Calcium Pyrophosphate, Hydrated Silica, Zilitol, Cellulose Gum, Flavor, Sodium Benzoate, Beta-Dioxide, Beta-Dioxide Potassium
[000333] [000333] The present invention is further described by the following examples which should not be considered as limiting the scope of the invention.
[000334] [000334] Aspergillus aculeatus CBS 172.66 was used as the source of DNA to obtain the coding region encoding the GH23 lysozyme candidate. According to the Central Bureau vor Schnimmelkulture, Aspergillus aculeatus CBS 172.66 was isolated by K.B.Raper in 1962 from tropical soil.
[000335] [000335] The strain of Aspergillus oryzae MT3568 was used for expression of the A. aculeatus gene encoding the enzyme. A. oryzae MT3568 is
[000336] [000336] The YP medium consisted of 10 g of yeast extract, 20 g of Bacto peptone, and deionized water up to 1 liter.
[000337] [000337] The LB medium consisted of 10 g of tryptone, 5 g of yeast extract, 5 g of sodium chloride, and deionized water up to 1 liter.
[000338] [000338] Horishoki's agar medium consisted of: 1% (w / v) dextrose, 1% soluble starch, 0.5% (w / v) peptone, 0.5% yeast extract ( w / v), MgSO4 · 7H2O 0.02% (w / v), K2HPO4 0.1% (w / v), and 15 g (w / v) of Bacto agar. Na2CO3 1% (w / v) was added separately after sterilization.
[000339] [000339] The PDA agar plates were composed by potato infusion (the potato infusion was made by boiling 300 g of sliced potatoes (washed but not peeled) in water for 30 minutes and then decanting or straining the broth through gauze Distilled water was then added until the total volume of the suspension was 1 liter, followed by the addition of 20 g (w / v) dextrose and 20 g (w / v) of agar powder. The medium was sterilized by autoclaving at 15 psi for 15 minutes (Bacteriological Analytical Manual, 8th Edition, Revision A, 1998).
[000340] [000340] The sucrose COVE plates were composed of 342 g of sucrose, 20 g of agar powder, 20 mL of COVE salts solution, and deionized water up to 1 liter. The medium was sterilized by autoclaving at 15 psi for 15 minutes (Bacteriological Analytical Manual, 8th Edition, Revision A, 1998). The medium was cooled to 60 ° C and acetamide was added to 10
[000341] [000341] LB agar plates consisted of 37 g of LB agar and deionized water up to 1 liter.
[000342] [000342] The COVE salt solution was composed of 26 g of MgSO4 · 7H2O, 26 g of KCl, 26 g of KH2PO4, 50 mL of COVE trace metal solution, and deionized water up to 1 liter.
[000343] [000343] The COVE trace metal solution was composed of 0.04 g of Na2B4O7 · 10H2O, 0.4 g of CuSO4 · 5H2O, 1.2 g of FeSO4 · 7H2O, 0.7 g of MnSO4 · H2O, 0, 8 g of Na2MoO4 · 2H2O, 10 g of ZnSO4 · 7H2O, and deionized water up to 1 liter.
[000344] [000344] Dap-4C medium consisted of 20 g dextrose, 10 g maltose, 11 g MgSO4 7H2O, 1 g KH2PO4, 2 g citric acid, 5.2 g K3PO4 H2O, 0.5 g of yeast extract (Difco), 1 ml of defoamer, 0.5 ml of trace metal KU6 solution, 2.5 g of CaCO3, and deionized water up to 1 liter. The medium was sterilized by autoclaving at 15 psi for 15 minutes (Bacteriological Analytical Manual, 8th Edition, Revision A, 1998). Before use, 3.5 mL of 50% sterile (NH4) 2HPO4 and 5 mL of% sterile lactic acid were added per 150 mL of medium.
[000345] [000345] The YP + 2% glucose medium was composed of 1% yeast extract, 2% peptone, and 2% glucose. Example 1: Lysozyme assay
[000346] [000346] Xanthomonas campestris is the production organism for the entire production of xanthan gum. The separation of Xanthomonas cells from the highly viscous xanthan solution is a costly process in industrial production (Homma et al., EP690072, Murofushi et al., EP718311, US5702927). Nowadays, the favored method for recovering xanthan from the fermentation liquid is precipitation with alcohol, mainly isopropanol, after pasteurization to destroy bacterial cells and enzymes (Cottrell, WI; Kang, SK Dev. (1978), “Xanthan gum: A unique bacterial
[000347] [000347] Commercially prepared xanthan gum (Sigma # G-1253) is dissolved in a buffered solution or bacteria growth medium up to 0.5% w / v in the presence of 0.7% agarose and then autoclaved. Enzyme, supernatant or whole organism preparations are either deposited in wells cut from the Bacto agar plates or deposited directly on the surface of the media. The preparations are able to form clarification zones on the plates. These clarification zones may indicate degradation of bacterial cell wall material. Liquid Clarification Test:
[000348] [000348] Commercially prepared xanthan gum is dissolved in a buffered solution in the presence or absence of sodium chloride. The solution is autoclaved and used for clarification studies of xanthan gum. Enzyme, supernatant or whole organism preparations are added to the test medium and incubated. The resulting treatments are measured on a spectrophotometer to determine the DO of the solution. Typically, a wavelength of 600 nm is used. Example 2: Cloning and characterization of the GH23 lysozyme from Aspergillus aculeatus (SEQ ID NO: 2)
[000349] [000349] Genomic sequence information was generated by the U.S. Department of Energy Joint Genome Institute (JGI). According to the Central
[000350] [000350] To generate genomic DNA for PCR amplification, Aspergillus aculeatus CBS 172.66 was propagated on PDA agar plates by cultivation at 26 ° C for 7 days. Spores collected from the PDA plates were used to inoculate 25 mL of YP + 2% glucose medium in a flask shaken with baffles and incubated at 26 ° C for 48 hours with shaking at 200 rpm.
[000351] [000351] Genomic DNA was isolated according to a modified FastDNA® SPIN protocol (Qbiogene, Inc., Carlsbad, CA, USA). Briefly, a FastDNA® SPIN Soil Kit (Qbiogene, Inc., Carlsbad, CA, USA) was used in a FastPrep® 24 Homogenization System (MP Biosciences, Santa Ana, CA, USA). Two mL of fungal material from the above cultures was collected by centrifugation at 14,000 x g for 2 minutes. The supernatant was removed and the pellet resuspended in 500 µL of deionized water. The suspension was transferred to a Lysing Matrix E FastPrep® tuvo (Qbiogene, Inc., Carlsbad, CA, USA) and 790 µL of sodium phosphate buffer and 100 µL of MT buffer from the FastDNA® SPIN Kit were added to the tube. The sample was then fixed on the FastPrep® Instrument (Qbiogene, Inc., Carlsbad, CA, USA) and processed for 60 seconds at a speed of 5.5 m / sec. The sample was then centrifuged at 14,000 x g for two minutes and the supernatant transferred to a clean EPPENDORF® tube. A 250 µL volume of PPS reagent from the Set
[000352] [000352] Two pairs of synthetic oligonucleotide primers shown in table 1 below were designed to PCR amplify the P8EH GH23 gene from Aspergillus aculeatus CBS 172.66, from genomic DNA. An IN-FUSION ™ Cloning Kit (Clontech, Mountain View, CA, USA) was used to clone the fragment directly into the pDau109 expression vector (WO 2005/042735). Table 1: Primers used for PCR Amplification of GH23 Gene GH23 Specific direct primer Specific reverse primer Aspergillus F- P8EH R- P8EH aculeatus CBS 5'-ACACAACTGGGGATCCACCAT 5'-AGATCTCGAGAAGCTTACTA
[000353] [000353] The bold letters represent the coding sequence. The underlined sequence is homologous to the pDau109 insertion sites.
[000354] [000354] The PCR reaction (25 µL) was composed of 12.5 µL of Mixture 2X IPROOF ™ HF Master, 0.5 µL of F-P24DZF primer (100 µM), 0.5 µL of R-P24DZF primer ( 100 µM), 0.5 µL of genomics (100 ng / µl), and 11 µL of deionized water. The PCR reaction was incubated on a DYAD® Dual-Block Thermal Cycler (Eppendorf Scientific, Inc., Westbury, MA, USA) programmed for 1 cycle at 98 ° C for 30 seconds; 30 cycles each at 98 ° C for 10 seconds, 55 ° C for 10 seconds, and 72 ° C for 60 seconds; and 1 cycle at 72 ° C for 10 minutes. The samples were cooled to 10ºC before removal and further processing.
[000355] [000355] Five µL of the PCR reaction were analyzed by electrophoresis on 1% agarose gel using TAE buffer where a product band of approximately 770 bp was observed. The remaining PCR reaction was purified using an ILLUSTRA ™ GFX ™ PCR DNA Purification Set and Gel Band according to the manufacturer's instructions.
[000356] [000356] The fragment was then cloned into pDau109 digested by Hind III and Bam HI using an IN-FUSION ™ Cloning Kit resulting in plasmid pP8EH. Cloning of the P24DZF gene in pDau109
[000357] [000357] The cloning protocol was performed according to the instructions of the IN-FUSION ™ Cloning Set generating a P24DZF GH23 construct. The treated plasmid and insert were transformed into E. coli Blue ™ cells (Clontech, Mountain View, CA, USA) according to the manufacturer's protocol and plated on LB plates supplemented with 50 µg of ampicillin per mL. After incubation at 37 ° C overnight, colonies were seen growing under selection on the LB plates with ampicillin. Ten colonies transformed with the P24DZF GH23 construct were cultured in LB medium supplemented with 50 µg ampicillin per ml and the plasmid was isolated using a 5Prime FASTPlasmid mini-set (5 PRIME GmbH, Königstrasse 4a, 22767 Hamburg, Germany) according to manufacturer's instructions.
[000358] [000358] Isolated plasmids were sequenced with vector primers and in order to determine a representative plasmid expression clone that was free of PCR errors. Characterization of Aspergillus aculeatus CBS genomic sequences
[000359] [000359] DNA sequencing of the Aspergillus aculeatus CBS172.66 genomic P24DZF GH23 clone was performed with an Applied Biosystems Model 3730xl Automated DNA Sequencer using BIG-DYE ™ terminator chemistry version 3.1 (Applied Biosystems, Inc., Foster City, CA, USA) and initiator walk strategy. The nucleotide sequence data was scrutinized for quality and
[000360] [000360] The nucleotide sequence and the deduced amino acid sequence of the Aspergillus aculeatus P24DZF GH23 gene are shown in SEQ ID NO: 1 and SEQ ID NO: 2, respectively. The coding sequence is 862 bp including the stop codon and is interrupted by a single 67 bp intron (nucleotides 572 to 638). The predicted encoded protein has 264 amino acids and is shown in SEQ ID NO: 2. Using the SignalP program (Nielsen et al., 1997, Protein Engineering 10: 1-6), a 19-residue signal peptide was predicted. The predicted mature protein contains 245 amino acids.
[000361] [000361] The strain of Aspergillus oryzae MT3568 was used for all experiments. Aspergillus oryzae MT3568 is a destroyed amdS (acetamidase) derivative of A. oryzae JaL355 (WO 2002/40694) in which pyrG auxotrophy was restored in the process of deactivating the amdS gene from A. oryzae. A. oryzae MT3568 protoplasts were prepared according to the method of European Patent EP0238023, pages 14-15. Fresh protoplasts of A. oryzae MT3568 were prepared and transformed with the P24DZF GH23 plasmid. Plasmid DNA from the miniprep procedure above was used to transform A. oryzae MT3568.
[000362] [000362] Six µL containing about 3.0 µg of total DNA were used for the transformation. DNA was gently added to 100 µL of A. oryzae MT3568 protoplasts and 250 µL of 60% PEG 4000 (Sigma-Aldrich cat. No. 95904). 60% PEG 400 (P / V) was prepared as follows: PEG 4000 powder was dissolved in double distilled H2O and then heated for 10-20 seconds in an 800 watt microwave oven until dissolved. The dissolved solution was cooled until
[000363] [000363] The plates were incubated at 37ºC for 3 or more days and then moved at 26ºC for two days. Spores from 8 individual colonies were chosen first by immersing a 10 µL white immersion pin (Nunc A / S, Denmark) in a 0.1% TWEEN® 80 solution, contact of the sporulating colony on the selection plate, and re-streaking with the pin on fresh plates of COVE sorbitol containing 10 mM acetamide. After 5 days at 26ºC, spores from the striated colonies were used to inoculate a 96-well deep plate (NUNC, cat. No. 260251, Thermoscientific, USA). Deep plate wells contained 500 µL of either YP + 2% glucose or DAP4C medium. The inoculated plate was sealed with gas permeable tape (89009-656, VWR.com). The plates were incubated stationary at 30 ° C for 5 days. Expression was verified by analyzing uLs of culture fluid collected on SDS-PAGE using a 10% Bis-Tris NUPAGE® gel (Invitrogen, Carlsbad, CA, USA) and Coomassie blue staining. One transformant was selected for further work and designated A. oryzae EXP03899.
[000364] [000364] EXP03899 spores were inoculated in YP + 2% glucose medium and DAP-4C-1 medium (100 mL in 500 mL Erlenmeyer flask with baffles). The cultures were incubated at 26ºC and 150 rpm, 3 days and if necessary 4 days. An SDS gel was used as above to test the amount of protein. Plaque testing for lysozyme activity
[000365] [000365] A Local test was carried out with xanthan gum, at pH 5, 7 and
[000366] [000366] A 1.5% Agarose solution (Invitrogen cat. 15510-02, electrophoresis grade) was prepared in the following buffers: pH ~ 5 - in water pH ~ 7 - in 0.02 M potassium phosphate pH 7 pH ~ 8 - in 0.02 M potassium phosphate pH 8
[000367] [000367] The agarose was autoclaved for 20 minutes at 121ºC. 0.5% xanthan gum (Sigma G1253) was dissolved in the melted 1.5% agarose and the mixture poured into Petri dishes. When the plates were ready, sample wells were made with a P-1000 pipette tip (3 mm diameter exclusion limit) attached to a vacuum line.
[000368] [000368] 20 μl of the EXP03899 culture fluid was deposited in the application wells and incubated at 37ºC overnight. Samples with lysozyme activity were observed by clarification zones where cell debris was observed in xanthan gum. The culture fluids of EXP03899 exhibited such a clarification zone while the Aspergillus oryzae MT3568 untransformed transformation host did not produce a remarkable clarification zone. The remaining EXP03899 culture fluid was filtered through a Fast PES Bottle top filter with an exclusion limit of 0.22 m and stored in aliquots at -20 ° C until further use. Example 3: Cloning and characterization of two genes encoding lysozyme GH24 from Acremonioum alkalophilum (SEQ ID NOs: 4 and 6)
[000369] [000369] Genome sequence information was generated by the U.S. Department of Energy Joint Genome Institute (JGI). According to the Central Bureau vor Schnimmelkulture, Acremonium alkalophilum CBS 114.92 was isolated by A. Yoneda in 1984 from pig slurry compost near Lake Tsukui, Japan. A preliminary genome assembly was downloaded from the JGI and analyzed using the Pedant-ProTM Sequence Analysis Suite (Biomax Informatics AG, Martinsried, Germany). Models
[000370] [000370] Acremonium alkalophilum CBS 114.92 was plated on Horikoshi agar, pH 9 for 7 days at 30 C. The mycelia were collected directly from the plate and the DNA isolated according to the FastDNA SPIN Set for Soil (www.mpbio.com ). DNA was eluted in 100 µL of 10 mM TRIS buffer, 0.1 mM EDTA, pH 7.5 and stored at 4 ° C until use.
[000371] [000371] The pairs of synthetic oligonucleotide primers shown in table 2 below were designed to PCR amplify the P242MS GH24 gene or the P244A7 GH24 gene from A. alkalophilum CBS114.92, from the genomic DNA of A. alkalophilum described in example 2 above. Table 2: Primers used for PCR Amplification of GH24 and GH25 Gene GH24 Specific direct primer Specific reverse primer GH24 P242MS F- P242MS R- P242MS from A. 5'-ACACAACTGGGGATCCACCAT 5'-AGATCTCGAGAAGCTTACTAAGGAGGAGGAGGAGCAGGGCCA .92 (SEQ ID NO: 11) (SEQ ID NO: 12) GH24 P244A7 F- P244A7 R- P244A7 by A. 5'-ACACAACTGGGGATCCACCAT 5'-AGATCTCGAGAAGCTTACTAAG alkalophilum GGTCTCTTTCAAGCAGCTC-3 'AGAGAGAGT NO: 13) (SEQ ID NO: 14)
[000372] [000372] The bold letters represent the coding sequence. The underlined sequence is homologous to the pDau109 insertion sites.
[000373] [000373] DNA sequencing of the GH24 genomic clone of Acremonium alkalophilum CBS114.92 was performed with an Applied Biosystems Model 3730xl Automated DNA Sequencer using BIG-DYE ™ terminator chemistry version 3.1 (Applied Biosystems, Inc., Foster City , CA, USA) and initiator walk strategy. The nucleotide sequence data was scrutinized for quality and all sequences
[000374] [000374] The nucleotide sequence and the deduced amino acid sequence of the Acremonium alkalophilum GH24 gene are shown in SEQ ID NO: 3 and SEQ ID NO: 4, respectively. The coding sequence is 628 bp including the stop codon and is interrupted by a single 67 bp intron (nucleotides 268 to 334) The predicted encoded protein has 186 amino acids. Using the SignalP program (Nielsen et al., 1997, Protein Engineering 10: 1-6), a 20-residue signal peptide was predicted. The predicted mature protein contains 166 amino acids. Gene P244A7 GH24
[000375] [000375] The nucleotide sequence and the deduced amino acid sequence of the P244A7 GH24 gene from Acremonium alkalophilum are shown in SEQ ID NO: 5 and SEQ ID NO: 6, respectively. The coding sequence is 782 bp including the terminating codon and is interrupted by two 81 bp introns (nucleotides 134 to 214) and 170 bp (nucleotides 346-515) The predicted encoded protein has 176 amino acids. Using the SignalP program (Nielsen et al., 1997, Protein Engineering 10: 1-6), a 19-residue signal peptide was predicted. The predicted mature protein contains 157 amino acids.
[000376] [000376] The plasmids for P242MS and P244A7 were produced and transformed into Aspergillus orzyzae as in example 2. Transformants with culture fluids that produced recombinant protein product were identified by SDS-PAGE as in example 2 and designated: EXP03865, in the case of P242MS, and EXP03890 in the case of P244A7. Culture fluids of EXP03865 and EXP03890 fermented in YP + 2% glucose and DAP4C media were seen on bacterial cell debris plates from
[000377] [000377] Initially, the antimicrobial activity of the culture supernatants and purified fractions containing the recombinantly expressed lysozymes was confirmed using an RDA as previously described by Lehrer et al. (Lehrer RI, Rosenman M, Harwig SS et al. (1991), ”Ultrasensitive assays for endogenous antimicrobial polypeptides”, J Immunol Methods, 137: 167–73), with several modifications. Soon, 30 mL of 1/10 molten Mueller – Hinton (MHB) buffer (Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989) with 1% agarose they were cooled to 42 ° C, supplemented to 5.0 × 105 cfu / mL with S. carnosus ATCC 51365 or E. coli DSM682 (ATCC 10536) and were poured into a single well omnitray plate (Nunc). The omnitray plate was overlaid with a TSP plate (Nunc) and allowed to solidify. After 1 h, the TSP plate was removed; leaving 96 1 mm wells in which 10 µL of the compound of interest could be tested.
[000378] [000378] 10 µL of the test solution are placed per well and the plates are incubated O / N at 37 ° C. The next day, the clarification zones did not indicate any growth of the test bacteria and therefore antimicrobial activity. The clarification zones were visualized by staining with MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide, a yellow tetrazole), which is reduced to purple formazan in living cells (Mosmann, Tim (1983), "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays", Journal of Immunological Methods 65 (1–2): 55-63). This staining provides a dark staining of living cells and no staining of the areas of
[000379] [000379] Aspergillus fumigatus GH25 lysozyme (prepared as disclosed in Korczynska et al, Acta Cryst. (2010) F66, 973-977) was included in the test as a reference. The purified samples shown in Table 3 were tested in the RDA assay. Table 3: Radial Diffusion Test of Lysozyme GH24 Lysozyme Conc. of stock Dilution 0.7 ug / uL 0.35 ug / uL GH24 dilution of A.alcalophilum SEQ 1.4 ug / uL 37.5 uL of enz. + 37.5 uL 18.8 uL of enzyme. + 56.2 uL ID NO: 6 of water of GH25 water from A.alcalophilum SEQ 0.77 ug / uL 68.2 uL of enz. + 6.8 µl of 34.1 µl of enzyme. + 40.9 uL ID NO: 8 water of GH25 water from A.fumigatus 12.2 ug / uL 4.3 uL of enz. + 70.6 µl of 2.2 µl enzy. + 72.8 uL of (reference) water water Measurement of clarification zones
[000380] [000380] The experiment was carried out in triplicate with all resulting in the same clarification zones / inhibition zones measured, see Figure 1. Table 4 below shows the clarification zones in mm. Table 4: Antimicrobial Clarification Areas for GH24 Lysozyme Against Staphylococcus carnosus and Escherichia coli. S. carnosus S. carnosus E. coli E. coli 0.7 µg / µL to 0.35 µg / µL to 0.7 µg / µL to 0.35 µg / µL GH24 of A.alcalophilum 12 10 16 14 SEQ ID NO: 6 GH25 from A.alcalophilum passed out 8 (cloudy) 6 (cloudy) SEQ ID NO: 8 GH25 from A.fumigatus 11 10 10 8 (reference)
[000381] [000381] Purified lysozyme having SEQ ID NO: 6 showed antimicrobial activity against viable cells of Gram-positive bacteria Staphylococcus carnosus and Gram-negative bacteria Escherichia coli.
[000382] [000382] Antimicrobial activity is not present in culture supernatants of the production host of unprocessed Aspergillus (results not shown).
[000383] [000383] Large areas of clarification with undefined borders were observed around the GH24 application zone of A. alcalophilum (SEQ ID NO: 6). Experience indicates that A. alcalophilum lysozyme
[000384] [000384] Lysozyme activity was determined by measuring the decrease (drop) in absorbance / optical density of a solution of Micrococcus lysodeikticus ATTC No. 4698 (Sigma-Aldrich M3770) or Exiguobacterium undea (DSM14481) resuspended in a 540 spectrophotometer nm. Substrate preparation of Micrococcus lysodeikticus
[000385] [000385] Before use, the cells were resuspended in citric acid - phosphate buffer pH 6.5 to a concentration of 0.5 mg cells / mL and the optical density (OD) at 540 nm was measured. The cell suspension was then adjusted such that the cell concentration was equivalent to OD540 = 1.0. The adjusted cell suspension was then stored in the cold before use. The resuspended cells were used within 4 hours. Preparation of citric acid - phosphate buffer pH 6.5
[000386] [000386] 29 ml of 0.1 M citric acid were mixed with 61 ml of 0.2 M Na2HPO4, and the pH was adjusted with HCl or NaOH to pH 6.5. Preparation of dry cells of Exiguobacterium undae (the substrate)
[000387] [000387] A culture of E. undae (DSM14481) was grown in 100 ml of LB medium (Fluka 51208, 25 g / L) in a 500 ml shake flask at ° C, 250 rpm overnight. The overnight culture was then centrifuged at 20 ° C and 5000 g for 10 minutes, and the pellet was washed twice in sterile milliQ water, and resuspended in Milli-Q water. The washed cells were centrifuged for 1 minute at 13,000 rpm and as much of the supernatant as possible was decanted. The washed cells were dried in a vacuum centrifuge for 1 hour. The cell pellet was resuspended in citric acid - phosphate buffer pH 6.5 such that the optical density (OD) at
[000388] [000388] The sample of lysozyme to be measured was diluted to a concentration of 100-200 mg protein enzyme / L in citric acid - phosphate buffer pH 6.5, and kept on ice until use. In a 96-well microtiter plate (Nunc), 200 L of the substrate was added to each well, and the plate was incubated at 25 ° C or 37 ° C for 5 minutes in a VERSAmax microplate reader (Molecular Devices). After incubation, the absorbance of each well was measured at 540 nm (start value). To start measuring the activity, 20 L of the diluted lysozyme sample was added to each substrate (200 L) and the kinetic measurement of absorbance at 540 nm was started for a minimum of 30 minutes up to 24 hours at 25 ° C or 37 ° Ç. The absorbance measured at 540 nm was monitored for each well and a drop in absorbance is seen over time if lysozyme has lysozyme activity.
[000389] [000389] The GH25 lysozyme of Aspergillus fumigatus (Korczynska et al (2010) supra.) Was included in the test as a reference and the results are shown in table 5 below. Table 5: Lysozyme activity of Lysozyme GH25 against Micrococcus lysodeikticus and Exiguobacterium undea as measured by Optical Density Drop Micrococcus lysodeikticus Exiguobacterium undae Temperature 37 ° C 25 ° C 37 ° C GH24 of A.alcalophilum SEQ ID NO: 4) NT - - GH24 from A.alcalophilum SEQ ID NO: 6) +++ + + GH25 from A.fumigatus (reference) + +++ +++ NT means not tested - Means no effect + means small effect ++ means medium effect ++ + means great effect Example 6: Expression of protein P242MS GH24 and protein P244A7 GH24 in Aspergillus oryzae
[000390] [000390] Constructs comprising the relevant lysozyme gene were used to construct expression vectors for Aspergillus. The Aspergillus expression vectors consist of an expression cassette based on the Aspergillus niger neutral amylase II promoter fused to the untranslated leader sequence of Aspergillus nidulans triose phosphate isomerase and the amyloglycosity terminator (Tamg) of Aspergillus niger. Also present in the plasmid was the amdS selective marker of Aspergillus from Aspergillus nidulans allowing growth in acetamide as the only nitrogen source. The expression plasmids were transformed into Aspergillus as described in example 3. For each of the constructs, 10-20 strains were isolated, purified and cultured in shake flasks. Example 7: Purification of P242MS GH24 protein and P244A7 GH24 protein in Aspergillus oryzae Purification of P242MS GH24 protein
[000391] [000391] The fermentation supernatant with lysozyme was filtered through a Fast PES Bottle top filter with an exclusion limit of 0.22 m. The pH was adjusted to 7.5 with 0.1 M NaOH and the resulting solution was concentrated (volume reduced by a factor of 8) in an Ultra Filtration Unit (Sartorius) with a membrane with an exclusion limit of 5 kDa.
[000392] [000392] After pretreatment, approximately 55 mL of the lysozyme containing solution was purified by Q Sepharose chromatography, approximately 50 mL on an XK26 column, using A TRIS buffer at 50 mM pH 7.5, and as B TRIS buffer 50 mM + 1 M NaCl pH 7.5. The column fractions were grouped based on the chromatogram (absorption at 280 and 254 nm) and SDS-PAGE analysis. The grouped fractions were subjected to buffer changes in 50 mM Na acetate, pH 5.5 and concentrated in a 250 ml PES filter, 5 kDa from Vivacell.
[000393] [000393] The molecular weight, as estimated by SDS-PAGE, was
[000394] [000394] The fermentation supernatant with lysozyme was filtered through a sandwich of four Whatman glass microfiber filters (2.7, 1.6, 1.2 and 0.7 micrometers) and then through a top filter Fast PES bottle with an exclusion limit of 0.22 m. The pH was adjusted to 4.5 with 10% acetic acid. After adjusting the pH, the solution became a little cloudy and this was removed by filtration through a Fast PES Bottle top filter with an exclusion limit of 0.22 m.
[000395] [000395] After pre-treatment, about 970 mL of the lysozyme containing solution were purified by chromatography on SP Sepharose, approximately 50 mL on an XK26 column, using 50 mM Na acetate pH 4.5 as buffer, and as buffer B 50 mM Na acetate + 1 M NaCl pH 4.5. The column fractions were grouped based on the chromatogram (absorption at 280 and 254 nm) and SDS-PAGE analysis. The pooled fractions were subjected to a buffer change in 50 mM Na acetate, pH 5.5 and concentrated using Amicon spin filters with an exclusion limit of 10 kDa.
[000396] [000396] The molecular weight, as estimated by SDS-PAGE, was approximately 20 kDa and the purity was> 90%.

权利要求:
Claims (17)
[1]
1. Isolated polypeptide having lysozyme activity, characterized by the fact that it is selected from the group consisting of: (a) a polypeptide having at least 90%, at least 91%, at least 92%, at least 93%, at least 94% at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the mature polypeptide of SEQ ID NO: 6; (b) a polypeptide having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96% at least 97%, at least 98%, at least 99% or 100% sequence identity with the mature polypeptide of SEQ ID NO: 2; (c) a polypeptide having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97% at least 98%, at least 99% or 100% sequence identity with the mature polypeptide of SEQ ID NO: 4; (d) a polypeptide encoded by a polynucleotide having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 1; (e) a polypeptide encoded by a polynucleotide having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the coding sequence of the mature SEQ ID polypeptide
NO: 3; (f) a polypeptide encoded by a polynucleotide having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 5; (g) a variant of the mature polypeptide of SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6, comprising a substitution, deletion, and / or insertion at one or more (e.g., several) positions , wherein the polypeptides differ by no more than 17 amino acids from the mature polypeptide of SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6; and (i) a fragment of the polypeptide of (a), (b), (c), (d), (e), (f) or (g) that has lysozyme activity.
[2]
2. Polypeptide according to claim 1, characterized in that it is selected from polypeptides comprising or consisting of SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6 or the mature polypeptide of SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6, where the mature polypeptide is selected from amino acids 20 to 264 of SEQ ID NO: 2, amino acids 21 to 186 of SEQ ID NO: 4 or amino acids at 176 of SEQ ID NO: 6.
[3]
3. Composition, characterized by the fact that it comprises the polypeptide as defined in any one of claims 1 to 2.
[4]
4. Detergent composition, characterized by the fact that it comprises the composition as defined in claim 3, and one or more components selected from the group comprising surfactants, adjuvants, hydrotopes, bleaching systems, polymers, fabric coloring agents, adjunct materials, dispersants , dye transfer inhibiting agents, fluorescent whitening agents, dirt release polymers and antideposition agents.
[5]
Detergent composition according to claim 4, characterized in that the composition comprises one or more additional enzymes selected from the group comprising proteases, amylases, lipases, cutinases, cellulases, endoglucanases, xyloglucanases, pectinases, pectin lyases, xanthases, peroxidases, haloperoxygenases, catalases and mannanases, or any mixture thereof.
[6]
6. Animal feed composition, characterized by the fact that it comprises the polypeptide as defined in any one of claims 1 to 2.
[7]
Animal feed composition according to claim 6, characterized by the fact that it additionally comprises one or more amylases; phytases; xylanases; galactanases; alpha-galactosidases; proteases, phospholipases, beta-glucanases, or any mixture thereof.
[8]
8. Animal feed additive, characterized in that it comprises at least one polypeptide as defined in any one of claims 1 to 2; and at least one fat-soluble vitamin, and / or at least one water-soluble vitamin, and / or at least one trace mineral.
[9]
Animal feed additive according to claim 8, characterized in that it additionally comprises one or more amylases; phytases; xylanases; galactanases; alpha-galactosidases; proteases, phospholipases, beta-glucanases, or any mixture thereof.
[10]
10. Use of the polypeptide as defined in any one of claims 1 to 2, characterized in that it is an inhibitor of biofilm formation.
[11]
11. Use of the polypeptide as defined in any one of claims 1 to 2, characterized by the fact that it is in a dental composition, in a detergent composition, or in animal feed.
[12]
12. Use of a polypeptide as defined in any one of claims 1 to 2, characterized in that it is for the breakdown of bacterial cell walls.
[13]
13. Isolated polynucleotide, characterized by the fact that it encodes the polypeptide as defined in any one of claims 1 to 2.
[14]
14. Nucleic acid construct or expression vector, characterized by the fact that it comprises the polynucleotide as defined in claim 13 operatively linked to one or more control sequences that direct the production of the polypeptide in an expression host.
[15]
15. Recombinant host cell, characterized by the fact that it comprises the polynucleotide as defined in claim 13 operationally linked to one or more control sequences that direct the production of the polypeptide.
[16]
16. Method of producing a polypeptide as defined in any one of claims 1 to 2, characterized by the fact that it comprises: (a) cultivation of a cell, which in its wild type produces the polypeptide, under conditions conducive to polypeptide production; and (b) recovering the polypeptide.
[17]
17. Method of producing a polypeptide having lysozyme activity, characterized by the fact that it comprises: (a) culturing the cell as defined in claim 15 under conditions conducive to the production of the polypeptide; and (b) recovering the polypeptide.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US10829750B2|2020-11-10|Polypeptides having lysozyme activity and polynucleotides encoding same

---

JP2014530598A|2014-11-20|Polypeptide having protease activity and polynucleotide encoding the same

---

WO2013189972A2|2013-12-27|Use of polypeptides having protease activity in animal feed and detergents

---

EP2934177B1|2017-10-25|Polypeptides having protease activiy and polynucleotides encoding same

---

US20150023945A1|2015-01-22|Lysozymes

同族专利:

---

公开号 | 公开日

---

JP6105615B2|2017-03-29|

---

AR088976A1|2014-07-23|

---

US10039300B2|2018-08-07|

---

MX353710B|2018-01-25|

---

WO2013076259A2|2013-05-30|

---

RU2619051C2|2017-05-11|

---

US20190153415A1|2019-05-23|

---

JP2015506667A|2015-03-05|

---

US20140325711A1|2014-10-30|

---

US10829750B2|2020-11-10|

---

US20200399625A1|2020-12-24|

---

AR113177A2|2020-02-05|

---

DK2782592T3|2017-06-19|

---

US20140380527A1|2014-12-25|

---

US9663775B2|2017-05-30|

---

CA2856593A1|2013-05-30|

---

BR112014012170A2|2020-06-23|

---

MX351916B|2017-11-03|

---

US10829751B2|2020-11-10|

---

ES2631605T3|2017-09-01|

---

US20170223986A1|2017-08-10|

---

MX2014006155A|2014-08-27|

---

EP2782593B1|2017-04-26|

---

RU2014125559A|2015-12-27|

---

PE20151745A1|2015-12-20|

---

CL2014001317A1|2014-11-07|

---

EP2782592B1|2017-03-15|

---

EP2782592A1|2014-10-01|

---

EP2782593A2|2014-10-01|

---

MX2014006216A|2014-08-21|

---

PL2782592T3|2017-09-29|

---

WO2013076259A3|2013-07-25|

---

WO2013076253A1|2013-05-30|

---

US10119130B2|2018-11-06|

---

IN2014CN04586A|2015-09-18|

---

US20180298365A1|2018-10-18|

---

AU2012342456A1|2014-05-22|

---

CN103957929A|2014-07-30|

---

CN103957929B|2017-06-30|

---

ES2624531T3|2017-07-14|

---

CN107090445A|2017-08-25|

---

ZA201403761B|2015-12-23|

---

AU2012342456B2|2016-11-24|

---

US9701952B2|2017-07-11|

---

US20170327808A1|2017-11-16|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB1296839A|1969-05-29|1972-11-22|

---

GB1483591A|1973-07-23|1977-08-24|Novo Industri As|Process for coating water soluble or water dispersible particles by means of the fluid bed technique|

---

GB1590432A|1976-07-07|1981-06-03|Novo Industri As|Process for the production of an enzyme granulate and the enzyme granuate thus produced|

---

DK187280A|1980-04-30|1981-10-31|Novo Industri As|RUIT REDUCING AGENT FOR A COMPLETE LAUNDRY|

---

US4355022A|1981-07-01|1982-10-19|Interon, Inc.|Method of dental treatment|

---

DK263584D0|1984-05-29|1984-05-29|Novo Industri As|ENZYMOUS GRANULATES USED AS DETERGENT ADDITIVES|

---

US4933287A|1985-08-09|1990-06-12|Gist-Brocades N.V.|Novel lipolytic enzymes and their use in detergent compositions|

---

EG18543A|1986-02-20|1993-07-30|Albright & Wilson|Protected enzyme systems|

---

DK122686D0|1986-03-17|1986-03-17|Novo Industri As|PREPARATION OF PROTEINS|

---

DE3750450T2|1986-08-29|1995-01-05|Novo Industri As|Enzyme-based detergent additive.|

---

US5389536A|1986-11-19|1995-02-14|Genencor, Inc.|Lipase from Pseudomonas mendocina having cutinase activity|

---

ES2076939T3|1987-08-28|1995-11-16|Novo Nordisk As|RECOMBINANT LUMPY OF HUMICOLA AND PROCEDURE FOR THE PRODUCTION OF RECOMBINANT LIPAS OF HUMICOLA.|

---

DK6488D0|1988-01-07|1988-01-07|Novo Industri As|ENZYMES|

---

AT129523T|1988-01-07|1995-11-15|Novo Nordisk As|SPECIFIC PROTEASE.|

---

JP3079276B2|1988-02-28|2000-08-21|天野製薬株式会社|Recombinant DNA, Pseudomonas sp. Containing the same, and method for producing lipase using the same|

---

JP2728531B2|1988-03-24|1998-03-18|ノボノルディスクアクティーゼルスカブ|Cellulase preparation|

---

US5776757A|1988-03-24|1998-07-07|Novo Nordisk A/S|Fungal cellulase composition containing alkaline CMC-endoglucanase and essentially no cellobiohydrolase and method of making thereof|

---

US5223409A|1988-09-02|1993-06-29|Protein Engineering Corp.|Directed evolution of novel binding proteins|

---

US5376288A|1989-06-21|1994-12-27|Noro Nordisk A/S|Detergent additive granulate and detergent|

---

GB8915658D0|1989-07-07|1989-08-23|Unilever Plc|Enzymes,their production and use|

---

DE69024323T2|1989-10-27|1996-10-17|Procter & Gamble|Antimicrobial method and formulation using Type II endoglycosidase and antimicrobial agent|

---

US5041236A|1989-10-27|1991-08-20|The Procter & Gamble Company|Antimicrobial methods and compositions employing certain lysozymes and endoglycosidases|

---

PT97110B|1990-03-23|1998-11-30|Gist Brocades Nv|PROCESS FOR CATALYSING ACCELERABLE REACTIONS BY ENZYMES, BY ADDING TO THE REACTIONAL MEDIUM OF TRANSGENIC PLANTS SEEDS AND FOR OBTAINING THE REFERED SEEDS|

---

US6395966B1|1990-08-09|2002-05-28|Dekalb Genetics Corp.|Fertile transgenic maize plants containing a gene encoding the pat protein|

---

DK115890D0|1990-05-09|1990-05-09|Novo Nordisk As|ENZYME|

---

JP3110452B2|1990-05-09|2000-11-20|ノボノルディスクアクティーゼルスカブ|Cellulase preparation comprising endoglucanase enzyme|

---

WO1992005249A1|1990-09-13|1992-04-02|Novo Nordisk A/S|Lipase variants|

---

IL99552D0|1990-09-28|1992-08-18|Ixsys Inc|Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof|

---

DE69133035T2|1991-01-16|2003-02-13|Procter & Gamble|Compact detergent compositions with highly active cellulases|

---

WO1992019729A1|1991-05-01|1992-11-12|Novo Nordisk A/S|Stabilized enzymes and detergent compositions|

---

RU2108320C1|1991-12-13|1998-04-10|Дзе Проктер Энд Гэмбл Компани|Activator of hydrogen peroxide and composition for whitening or disinfection on its base|

---

US5595892A|1991-12-20|1997-01-21|Shin-Etsu Chemical Co., Ltd.|Process for preparation of purified xanthan gum|

---

DK72992D0|1992-06-01|1992-06-01|Novo Nordisk As|ENZYME|

---

DK88892D0|1992-07-06|1992-07-06|Novo Nordisk As|CONNECTION|

---

EP0651794B1|1992-07-23|2009-09-30|Novozymes A/S|MUTANT $g-AMYLASE, DETERGENT AND DISH WASHING AGENT|

---

EP1431389A3|1992-10-06|2004-06-30|Novozymes A/S|Cellulase variants|

---

DE69415659T3|1993-02-11|2010-05-12|Genencor International, Inc., Palo Alto|OXIDATIVE STABLE ALPHA AMYLASE|

---

AT287946T|1993-04-27|2005-02-15|Genencor Int|NOVEL LIPASE VARIATIONS FOR USE IN DETERGENTS|

---

DK52393D0|1993-05-05|1993-05-05|Novo Nordisk As|

---

FR2704860B1|1993-05-05|1995-07-13|Pasteur Institut|NUCLEOTIDE SEQUENCES OF THE LOCUS CRYIIIA FOR THE CONTROL OF THE EXPRESSION OF DNA SEQUENCES IN A CELL HOST.|

---

JP2859520B2|1993-08-30|1999-02-17|ノボノルディスクアクティーゼルスカブ|Lipase, microorganism producing the same, method for producing lipase, and detergent composition containing lipase|

---

EP0724631A1|1993-10-13|1996-08-07|Novo Nordisk A/S|H 2?o 2?-stable peroxidase variants|

---

JPH07143883A|1993-11-24|1995-06-06|Showa Denko Kk|Lipase gene and mutant lipase|

---

DE4343591A1|1993-12-21|1995-06-22|Evotec Biosystems Gmbh|Process for the evolutionary design and synthesis of functional polymers based on shape elements and shape codes|

---

US5605793A|1994-02-17|1997-02-25|Affymax Technologies N.V.|Methods for in vitro recombination|

---

WO1995022615A1|1994-02-22|1995-08-24|Novo Nordisk A/S|A method of preparing a variant of a lipolytic enzyme|

---

EP1632557B1|1994-03-08|2011-02-23|Novozymes A/S|Novel alkaline cellulases|

---

EP0755442B1|1994-05-04|2002-10-09|Genencor International, Inc.|Lipases with improved surfactant resistance|

---

DE69523052T2|1994-06-03|2002-06-20|Novo Nordisk Biotech Inc|PURIFIED MYCELIOPHTHORA LACCASES AND NUCLEIC ACIDS CODING THEM|

---

WO1995035381A1|1994-06-20|1995-12-28|Unilever N.V.|Modified pseudomonas lipases and their use|

---

AU2884695A|1994-06-23|1996-01-19|Unilever Plc|Modified pseudomonas lipases and their use|

---

JP3741734B2|1994-06-30|2006-02-01|信越化学工業株式会社|Xanthan gum recovery and purification method|

---

EP0777737B1|1994-06-30|2005-05-04|Novozymes Biotech, Inc.|Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein|

---

AU3604595A|1994-10-06|1996-05-02|Novo Nordisk A/S|An enzyme and enzyme preparation with endoglucanase activity|

---

BE1008998A3|1994-10-14|1996-10-01|Solvay|Lipase, microorganism producing the preparation process for the lipase and uses thereof.|

---

KR970707275A|1994-10-26|1997-12-01|안네 제케르|An enzyme having lipolytic activity |

---

AR000862A1|1995-02-03|1997-08-06|Novozymes As|VARIANTS OF A MOTHER-AMYLASE, A METHOD TO PRODUCE THE SAME, A DNA STRUCTURE AND A VECTOR OF EXPRESSION, A CELL TRANSFORMED BY SUCH A DNA STRUCTURE AND VECTOR, A DETERGENT ADDITIVE, DETERGENT COMPOSITION, A COMPOSITION FOR AND A COMPOSITION FOR THE ELIMINATION OF|

---

JPH08228778A|1995-02-27|1996-09-10|Showa Denko Kk|New lipase gene and production of lipase using the same|

---

CN102080070B|1995-03-17|2016-01-20|诺沃奇梅兹有限公司|new endoglucanase|

---

JP3741751B2|1995-07-11|2006-02-01|信越化学工業株式会社|Method for modifying xanthan gum|

---

DE69633825T2|1995-07-14|2005-11-10|Novozymes A/S|Modified enzyme with lipolytic activity|

---

DE19528059A1|1995-07-31|1997-02-06|Bayer Ag|Detergent and cleaning agent with imino disuccinates|

---

ES2221934T3|1995-08-11|2005-01-16|Novozymes A/S|NEW LIPOLITIC ENZYMES.|

---

US5763385A|1996-05-14|1998-06-09|Genencor International, Inc.|Modified α-amylases having altered calcium binding properties|

---

AU3938997A|1996-08-26|1998-03-19|Novo Nordisk A/S|A novel endoglucanase|

---

CN100362100C|1996-09-17|2008-01-16|诺沃奇梅兹有限公司|Cellulase variants|

---

WO1998015257A1|1996-10-08|1998-04-16|Novo Nordisk A/S|Diaminobenzoic acid derivatives as dye precursors|

---

BR9712360A|1996-10-18|2001-06-19|Procter & Gamble|Detergent compositions|

---

EP0932667B1|1996-11-04|2008-10-01|Novozymes A/S|Subtilase variants and compositions|

---

CA2270593C|1996-11-04|2005-06-07|Novo Nordisk A/S|Subtilase variants and compositions|

---

WO1998034946A1|1997-02-12|1998-08-13|Massachusetts Institute Of Technology|Daxx, a novel fas-binding protein that activates jnk and apoptosis|

---

JP2997800B2|1997-12-01|2000-01-11|農林水産省食品総合研究所長|Cell wall lytic enzyme gene, vector containing the gene and transformant|

---

US5955310A|1998-02-26|1999-09-21|Novo Nordisk Biotech, Inc.|Methods for producing a polypeptide in a bacillus cell|

---

CN1323166A|1998-10-15|2001-11-21|Dsm公司|Antimicrobial enzymes in animal feed|

---

DK1124949T3|1998-10-26|2006-11-06|Novozymes As|Construction and screening of a DNA library of interest in filamentous fungal cells|

---

EP1137761B1|1998-12-04|2007-08-01|Novozymes A/S|Cutinase variants|

---

JP4620253B2|1999-03-22|2011-01-26|ノボザイムス，インコーポレイティド|Promoter for gene expression in fungal cells|

---

US6939702B1|1999-03-31|2005-09-06|Novozymes A/S|Lipase variant|

---

US6710023B1|1999-04-19|2004-03-23|Procter & Gamble Company|Dishwashing detergent compositions containing organic polyamines|

---

EP2617294A1|2001-02-14|2013-07-24|Ventria Bioscience|Expression of human milk proteins in transgenic plants|

---

AU6008501A|2000-06-02|2001-12-11|Novozymes As|Cutinase variants|

---

WO2001098214A1|2000-06-19|2001-12-27|Novozymes Biotech, Inc.|Methods for eliminating the formation of biofilm|

---

US20020104126A1|2000-10-18|2002-08-01|Pogue Gregory P.|Production of bovine lysozyme by plant viral vectors|

---

WO2002040694A2|2000-11-17|2002-05-23|Novozymes A/S|Heterologous expression of taxanes|

---

US7151204B2|2001-01-09|2006-12-19|Monsanto Technology Llc|Maize chloroplast aldolase promoter compositions and methods for use thereof|

---

EP1423023B1|2001-07-13|2006-12-06|Danisco A/S|Composition having bacteristatic and bactericidal activity against bacterial spores and vegetative cells and process for treating foods therewith|

---

GB0127036D0|2001-11-09|2002-01-02|Unilever Plc|Polymers for laundry applications|

---

EP1478755B1|2002-02-19|2009-05-27|Novozymes A/S|Expression cloning methods in filamentous fungi|

---

DE10237317B4|2002-08-15|2010-04-08|3M Espe Ag|Enzyme-containing composition, process for their preparation and their use|

---

CA2404356A1|2002-09-18|2004-03-18|Canadian Inovatech Inc.|Gram-positive antibacterial composition and method for use|

---

GB2379166A|2002-10-22|2003-03-05|Dsm Nv|Animal feed|

---

RU2232818C1|2002-11-06|2004-07-20|Федеральное государственное учреждение Российский научно-исследовательский противочумный институт "Микроб"|Method for isolating chromosomal dna from bacterial cells of plague pathogen, yersinia pestis|

---

GB0314211D0|2003-06-18|2003-07-23|Unilever Plc|Laundry treatment compositions|

---

GB0314210D0|2003-06-18|2003-07-23|Unilever Plc|Laundry treatment compositions|

---

EP1633843A1|2003-06-18|2006-03-15|Unilever Plc|Laundry treatment compositions|

---

DK1682655T3|2003-10-30|2010-01-11|Novozymes As|Carbohydrate binding modules from a new family|

---

DE602004031662D1|2003-12-03|2011-04-14|Procter & Gamble|perhydrolase|

---

EP1711529A1|2004-01-21|2006-10-18|Novozymes A/S|Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell|

---

AU2005215852B2|2004-02-25|2010-04-22|Novozymes A/S|Fungal cell wall degrading enzyme|

---

JP2006182662A|2004-12-27|2006-07-13|Lion Corp|Dentifrice composition|

---

WO2006113314A1|2005-04-15|2006-10-26|The Procter & Gamble Company|Liquid laundry detergent compositions with modified polyethyleneimine polymers and lipase enzyme|

---

MX2007012612A|2005-04-15|2008-01-11|Basf Ag|Amphiphilic water-soluble alkoxylated polyalkylenimines with an internal polyethylene oxide block and an external polypropylene oxide block.|

---

WO2006130575A2|2005-05-31|2006-12-07|The Procter & Gamble Company|Polymer-containing detergent compositions and their use|

---

US8518675B2|2005-12-13|2013-08-27|E. I. Du Pont De Nemours And Company|Production of peracids using an enzyme having perhydrolysis activity|

---

WO2007087259A2|2006-01-23|2007-08-02|The Procter & Gamble Company|Enzyme and photobleach containing compositions|

---

JP2009523900A|2006-01-23|2009-06-25|ザプロクターアンドギャンブルカンパニー|Composition comprising lipase and bleach catalyst|

---

DK1979477T3|2006-01-23|2017-06-26|Novozymes As|lipase variants|

---

US8022027B2|2006-01-23|2011-09-20|The Procter & Gamble Company|Composition comprising a lipase and a bleach catalyst|

---

AR059158A1|2006-01-23|2008-03-12|Procter & Gamble|COMPOSITIONS CONTAINING ENZYMES AND DYE AGENTS FOR FABRICS|

---

US7790666B2|2006-01-23|2010-09-07|The Procter & Gamble Company|Detergent compositions|

---

EP1979452A2|2006-01-23|2008-10-15|The Procter and Gamble Company|Detergent compositions|

---

WO2007109750A2|2006-03-22|2007-09-27|Novozymes North America, Inc.|Fermentation processes|

---

ES2349236T3|2006-05-31|2010-12-29|Basf Se|AMPHYFY POLYMERS OF GRAFT WITH BASE IN POLYCHYLENE OXIDES AND VINYL ESTERS.|

---

EP1876226B1|2006-07-07|2011-03-23|The Procter & Gamble Company|Detergent compositions|

---

KR20100016416A|2007-04-10|2010-02-12|새인트 시메온 엘디에이|Novel compositions containing lysozyme and c-1/c-4 polysaccharides and use thereof in oral care, cosmetology and dermatology, contraception, urology and gynecology|

---

ES2568784T3|2008-01-04|2016-05-04|The Procter & Gamble Company|A laundry detergent composition comprising glycosyl hydrolase|

---

CN101945996A|2008-02-11|2011-01-12|丹尼斯科美国公司|Has an active enzyme of microbial lytic from Trichodermareesei|

---

US20090209447A1|2008-02-15|2009-08-20|Michelle Meek|Cleaning compositions|

---

CN101960008B|2008-02-29|2016-04-13|诺维信公司|There are the polypeptide of lipase activity and the polynucleotide of this polypeptide of coding|

---

EP2367923A2|2008-12-01|2011-09-28|Danisco US Inc.|Enzymes with lipase activity|

---

BRPI1013219A2|2009-03-06|2016-03-29|Huntsman Adv Mat Switzerland|method for textile enzymatic bleaching-bleaching|

---

EP2408805A2|2009-03-18|2012-01-25|Danisco US Inc.|Fungal cutinase from magnaporthe grisea|

---

US20120058527A1|2009-03-23|2012-03-08|Danisco Us Inc.|Cal a-related acyltransferases and methods of use, thereof|

---

WO2010115156A2|2009-04-03|2010-10-07|Synthetic Genomics, Inc.|Endophytic fungus and uses therefor|

---

WO2011084417A1|2009-12-21|2011-07-14|Danisco Us Inc.|Detergent compositions containing geobacillus stearothermophilus lipase and methods of use thereof|

---

BR112012017060A2|2009-12-21|2016-11-29|Danisco Us Inc|"Thermobifide lipase-containing detergent compositions, method for hydrolyzing a lipid present in a dirt or stain on a surface and method for performing a transesterification reaction|

---

WO2011084599A1|2009-12-21|2011-07-14|Danisco Us Inc.|Detergent compositions containing bacillus subtilis lipase and methods of use thereof|

---

EP2539447B1|2010-02-25|2017-07-26|Novozymes A/S|Variants of a lysozyme and polynucleotides encoding same|

---

WO2011150157A2|2010-05-28|2011-12-01|Danisco Us Inc.|Detergent compositions containing streptomyces griseus lipase and methods of use thereof|

---

JP6027092B2|2011-04-08|2016-11-16|ダニスコ・ユーエス・インク|Composition|

---

ES2624531T3|2011-11-25|2017-07-14|Novozymes A/S|Polypeptides that have lysozyme activity and polynucleotides encoding them|ES2624531T3|2011-11-25|2017-07-14|Novozymes A/S|Polypeptides that have lysozyme activity and polynucleotides encoding them|

---

JP6591998B2|2014-03-28|2019-10-16|ノボザイムス アクティーゼルスカブ|Resolubilization of protein crystals at low pH|

---

US20160030528A1|2014-07-01|2016-02-04|Vanderbilt University|Antimicrobial muramidase|

---

BR112017003847A2|2014-08-28|2018-02-27|Renescience As|process for solubilizing waste such as municipal solid waste , and process for producing a fermentation product|

---

EP3317293A4|2015-07-02|2019-03-20|Novozymes A/S|Animal feed compositions and uses thereof|

---

WO2017001703A1|2015-07-02|2017-01-05|Novozymes A/S|Methods of improving animal performance|

---

PE20181084A1|2015-07-02|2018-07-05|Novozymes As|FEED COMPOSITIONS FOR ANIMALS AND USES OF THE SAME|

---

CN108289478A|2015-10-13|2018-07-17|帝斯曼知识产权资产管理有限公司|Include the feed addictive for aquatic animal of essential oil and lysozyme|

---

JP6154091B1|2015-12-02|2017-06-28|日清オイリオグループ株式会社|Oil composition for coating|

---

US20210032614A1|2016-02-16|2021-02-04|Monaghan Mushrooms Group|Fungal polypeptides having lysozyme activity|

---

WO2017199094A1|2016-05-20|2017-11-23|Novobind Livestock Therapeutics Inc.|Antibodies against microorganisms and uses thereof|

---

CN105861468B|2016-06-07|2019-12-06|江南大学|Method for improving antibacterial performance of pig lysozyme by fusing HLH functional domain at N end|

---

CN106046173B|2016-06-07|2019-05-10|江南大学|A kind of method that N-terminal fusion poly hexapeptide improves pig lysozyme antibiotic performance|

---

CN106701373A|2016-12-11|2017-05-24|深圳市美益洁生物科技有限公司|Tea set bio-enzyme degerming cleaner and preparation method and application thereof|

---

MX2019007233A|2016-12-21|2019-09-09|Novozymes As|Polypeptides having lysozyme activity, polynucleotides encoding same and uses and compositions thereof.|

---

WO2018113745A1|2016-12-21|2018-06-28|Novozymes A/S|Polypeptides having lysozyme activity, polynucleotides encoding same and uses and compositions thereof|

---

BR112019013574A2|2017-01-04|2020-06-23|Novozymes A/S|MICROBIAL LYSOZYME OR A COMPOSITION, METHOD OF PREVENTION, RELIEF OR TREATMENT OF IRRITABLE GUT SYNDROME OR INFLAMMATORY INTESTINAL DISEASE, AND METHOD OF IMPROVING INTESTINAL HEALTH IN HUMAN BEINGS.|

---

US20200109388A1|2017-04-03|2020-04-09|Novozymes A/S|Recovery Process|

---

US20210137075A1|2017-05-09|2021-05-13|Novozymes A/S|Animal Chew Toy with Dental Care Composition|

---

WO2018206001A1|2017-05-12|2018-11-15|Novozymes A/S|Polypeptides having lysozyme activity, polynucleotides encoding same and uses and compositions thereof|

---

EP3668991A4|2017-08-18|2021-06-09|President and Fellows of Harvard College|Nanocarriers for the delivery of active ingredients|

---

CN108251440B|2017-12-18|2021-04-13|宁波大学|Sinonovacula constricta lysozyme gene, coding protein and construction method and application of recombinant sinonovacula constricta lysozyme gene engineering bacteria|

---

CN111491518A|2017-12-20|2020-08-04|帝斯曼知识产权资产管理有限公司|Animal feed compositions comprising muramidase and uses thereof|

---

EP3728578A1|2017-12-20|2020-10-28|DSM IP Assets B.V.|Animal feed compositions and uses thereof|

---

CN110115776A|2018-02-07|2019-08-13|沈阳药科大学|A kind of absorbable spherex styptic powder and its application with antibacterial activity|

---

EP3761803A1|2018-03-05|2021-01-13|Novozymes A/S|Ruminant feed composition comprising a muramidase|

---

US20210112827A1|2018-04-25|2021-04-22|Novozymes A/S|Animal Feed Compositions and Uses Thereof|

---

BR112021004464A8|2018-09-11|2021-06-01|Dsm Ip Assets Bv|composition of animal feed and its use|

---

US20210337828A1|2018-09-11|2021-11-04|Dsm Ip Assets B.V.|Animal feed composition and use thereof|

---

BR112021004501A2|2018-09-11|2021-06-08|Dsm Ip Assets B.V.|composition of animal feed and its use|

---

WO2020053274A1|2018-09-11|2020-03-19|Dsm Ip Assets B.V.|Animal feed composition and use thereof|

---

EP3850090A1|2018-09-11|2021-07-21|Novozymes A/S|Stable granules for feed compositions|

---

KR20210057773A|2018-09-11|2021-05-21|디에스엠 아이피 어셋츠 비.브이.|Animal feed composition and use thereof|

---

BR112021004833A2|2018-09-17|2021-06-08|Dsm Ip Assets B.V.|animal feed compositions and their uses|

---

EP3852545A1|2018-09-17|2021-07-28|DSM IP Assets B.V.|Animal feed compositions and uses thereof|

---

WO2020058225A1|2018-09-17|2020-03-26|Dsm Ip Assets B.V.|Animal feed compositions and uses thereof|

---

US20220031815A1|2018-09-17|2022-02-03|Dsm Ip Assets B.V.|Animal feed composition and use thereof|

---

BR112021004826A2|2018-09-17|2021-06-08|Dsm Ip Assets B.V.|animal feed compositions and their uses|

---

WO2020099490A1|2018-11-14|2020-05-22|Novozymes A/S|Oral care composition comprising enzymes|

---

EP3898962A2|2018-12-21|2021-10-27|Novozymes A/S|Polypeptides having peptidoglycan degrading activity and polynucleotides encoding same|

---

EP3898985A1|2018-12-21|2021-10-27|Novozymes A/S|Tandem protein expression|

---

CN110501983B|2019-07-31|2021-03-26|农业农村部南京农业机械化研究所|Expert control system and control method based on batch-type coating machine|

---

CN114127124A|2019-08-06|2022-03-01|诺维信公司|Fusion proteins for enhanced enzyme expression|

---

WO2021074287A1|2019-10-17|2021-04-22|Dsm Ip Assets B.V.|Animal feed compositions and uses thereof|

---

WO2021202479A1|2020-04-03|2021-10-07|Novozymes A/S|Submerged fermentation process|

---

CN111471621B|2020-04-20|2021-09-28|河北萌帮水溶肥料股份有限公司|Water area microbacterium MB338 and application thereof|

---

CN111398537A|2020-04-25|2020-07-10|燕京啤酒有限责任公司|Method for predicting and regulating bubble-holding index of finished beer|

---

CN111378635B|2020-05-29|2020-10-16|中国农业科学院北京畜牧兽医研究所|Method for co-expressing lysozyme and xylanase and method for preparing feed additive for replacing antibiotics|

---

WO2022043273A2|2020-08-24|2022-03-03|Novozymes A/S|Oral care composition comprising a fructanase|

---

WO2022047149A1|2020-08-27|2022-03-03|Danisco Us Inc|Enzymes and enzyme compositions for cleaning|

---

CN113769148A|2021-09-27|2021-12-10|中国科学院微生物研究所|Application of PslG protein in contact lens care solution|

法律状态:
2020-07-07| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2021-02-23| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-11-03| B350| Update of information on the portal [chapter 15.35 patent gazette]|

---

2021-11-23| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

EP11190690|2011-11-25|

---

EP11190690.5|2011-11-25|

---

PCT/EP2012/073493|WO2013076259A2|2011-11-25|2012-11-23|Polypeptides having lysozyme activity and polynucleotides encoding same|

---